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Abstract 
Background and objectives:  
Calcineurin inhibitors (CNIs) are widely used in organ transplantation (Tx). Due to the 
narrow therapeutic window, regular drug monitoring is necessary to balance sufficient 
efficacy with minimal toxicity. Until now, the monitoring has mainly been based on 
measurements of drug concentrations. However, despite concentration guided dosing of CNIs, 
patients still suffer from acute or chronic rejection and CNI related toxicity during CNI 
therapy. Pharmacokinetic (PK) measurements do not necessarily reflect the CNI effect on 
immune cells and pharmacodynamic (PD) monitoring of the nuclear factor of activated T 
cells (NFAT)-regulated gene expression has been suggested as a promising supplementary 
tool for individualizing CNI therapy.  
The objective of the present project was to develop and validate an assay to examine 
NFAT-regulated genes as PD biomarkers of CNI response in blood samples from renal 
transplant recipients.  
Materials and methods:  
Heparinized peripheral whole blood samples with and without addition of different 
immunosuppressive drugs were stimulated with phorbol 12-myristate13-acetate (PMA) and 
ionomycin for up to 72 hours at 37°C. Samples from renal allograft recipient were drawn 
before and 1.5 hours after tacrolimus (Tac) dosing and stimulated with PMA and ionomycin 
for 3 hours at 37°C. Following cell lysis, total RNA was isolated with the automated MagNA 
Pure LC instrument and reverse transcribed using Transcriptor First Strand cDNA Synthesis 
Kit (Roche). The expression of NFAT-regulated genes, interleukin 2 (IL2), interferon-γ 
(IFNG) and colony-stimulating factor 2 (granulocyte-monocyte) (CSF2) was determined by 
real-time PCR on the LightCycler® 480 instrument (Roche). The calculations included 
normalization to the expression of three reference genes, 5-aminolevulinate synthase 1 
(ALAS1), beta-2-microglobulin (B2M) and ribosomal protein L13A (RPL13A), and PCR 
efficiency correction.  
Abstract 
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Results:  
SYBR Green I analysis, gel electrophoresis and Sanger sequencing demonstrated selective 
amplification of the target gene sequences. Standard curves were linear over a range 
corresponding to starting concentrations of 107 to 102 cDNA templates per reaction. The 
between and within assay coefficient of variability (CV) was ≤ 19.8% and ≤ 14.8%, 
respectively.  The maximum response to PMA and ionomycin was observed after 3 hours 
incubation, resulting in 120 000, 20 000 and 8000 fold increases of IL2, IFNG and CSF2 
expression, respectively. Ex vivo exposure to different immunosuppressive drugs and 
concentrations, demonstrated that inhibition of NFAT-regulated gene expression seemed to be 
relatively CNI specific and inversely correlated to CNI concentration. There was a large 
variability of NFAT-regulated gene expression between patients before Tx. About one week 
after Tx, 4 of 5 patients demonstrated residual gene expression ≤ 13%. Three of these patients 
demonstrated Tac C0 levels within the therapeutic target range.  
Conclusions:  
Several studies support the potential of NFAT-regulated gene expression as a PD tool for 
further individualization and improvement of CNI therapy. A reverse transcription (RT) and 
real-time PCR assay was developed and validated to determine IL2, IFNG and CSF2 gene 
expressions in whole blood samples.  
The preliminary results of the present study support the use of NFAT-regulated gene 
expression as PD biomarker of Tac response. However, the value of monitoring 
NFAT-regulated gene expression during Tac therapy needs to be determined in prospective 
intervention trials with larger patient cohorts. 
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1 Introduction 
1.1 Transplantation 
Allotransplantation (Allo-Tx, frequently referred to only as transplantation) involves the 
transfer of cells, tissues or organs between individuals of the same species. The procedure 
allows the replacement of an irreversibly damaged organ. Today, organ transplantation (Tx) 
has become a vitally important treatment for patients with end-stage organ failure. The most 
frequently transplanted organs in Norway are kidneys, liver, heart, lungs and pancreas 
(Figure 1).  
Oslo University Hospital, Rikshospitalet, has the national function of all organ transplants in 
Norway, while 28 other hospitals in the country can identify potential donors.  
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Figure 1: Number of transplants per year from 2001 to 2010. (Data from the annual report for organ donation 
and transplantation January 1 – September 30 2010 at Oslo University Hospital, Rikshospitalet). 
__________________________________________________________________________ 
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1.1.1 Renal transplantation (Tx) 
The world’s first successful renal Tx with a graft from a living related donor was performed 
in 1954 in Boston, USA. Two years later, the first Tx in Norway of a kidney from a living 
unrelated donor was performed. Despite blood-group (ABO) and tissue (human leukocyte 
antigen) incompatibility, the patient lived for 30 days after Tx. [1] Over the years, there have 
been important breakthroughs in surgical skills, tissue typing and immunosuppressive drugs. 
Consequently, the number of transplantations and the patient survival rates have increased [2].  
Renal Tx is an option for patients with irreversible chronic end-stage renal failure (according 
to The Kidney Disease Outcomes Quality Initiative: stage 5). Several studies have reported 
increased survival among renal allograft recipients compared to patients in dialysis [3,4]. 
Thus, renal Tx is the treatment of choice for many patients with end-stage renal disease [5-7]. 
The most common causes of chronic renal failure among all age groups are diabetes, chronic 
glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus and interstitial 
nephritis [8]. 
 
 
1.2 Immune response 
1.2.1 Allorecognition 
The powerful immune responses that occur against tissue or the transplanted organ are related 
to the genetic differences between donor and recipient.  
The main barrier to allo-Tx is recognition of the major histocompatibility complex (MHC) 
molecules expressed on donor tissue. In humans, the MHC is referred to as the human 
leukocyte antigen (HLA) system and the gene complex is located on chromosome 6. HLA 
genes are divided into four classes based on their functions and structures. Diversity of 
antigen presentation is mediated by class I and II, while class III and IV includes components 
of the complement system, cytokines and heat shock proteins.  
The HLA class I molecules are expressed on almost all nucleated cells of the body and 
present antigens of intracellular origin to CD8+ cytotoxic T cells. This represents a pivotal 
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defense function against cells that are damaged or infected with viruses. Class II molecules 
are constitutively expressed on antigen-presenting cells (APCs) such as dendritic cells, B cells 
and macrophages. These molecules can present foreign peptides derived from exogenous 
antigens to CD4+ helper T cells.  
HLA class I molecules consist of an alpha chain, encoded by HLA genes (HLA-A, HLA-B and 
HLA-C), and beta-2-microglobulin (B2M), while the class II molecules are heterodimers of 
alpha and beta chains, which are both encoded by HLA genes (HLA-DP, HLA-DQ and 
HLA-DR loci). The HLA genes are highly polymorphic and each individual express a unique 
set of HLA molecules [9]. Several studies have shown that a good match between donor and 
recipients HLA molecules is significant for the outcome after Tx. Especially, matching at the 
HLA-DR loci has been reported to have significant impact on graft survival [10,11]. The HLA 
class I and II molecules represent the most important antigenic differences between 
individuals and are also known as Tx antigens [12,13].  
ABO blood-group antigens are expressed on the erythrocytes and on most epithelial and 
endothelial cells. Previously, ABO incompatibility was considered an absolute 
contraindication for renal Tx. Following the implementation of pre transplant desensitization 
protocols, including removal of preexisting ABO antibodies, Tx can now be performed across 
ABO blood group barriers [14]. 
 
1.2.2 Immune activation 
T cell activation is normally triggered by the recognition of a foreign peptide/HLA complex 
by the T cell receptor complex, followed by the interaction between T cell membrane 
receptors and APC membrane ligands (adhesion and costimulatory molecules). This induces 
intracellular signaling pathways and initiates the transcription of several nuclear factors of 
activated T cells (NFAT)-regulated genes, which are essential for the proliferation and 
differentiation of T cells. One of the key mediators in this context is the cytokine interleukin 2 
(IL2).  
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1.2.3 Allograft rejection 
Following allo-Tx, an immune response can be initiated by different immunologic recognition 
mechanisms.  
1. In the direct pathway of antigen presentation, the HLA molecules on APCs of the 
donor are directly recognized by the T cells of the recipient.  
2. The indirect pathway of antigen presentation involves recipient APCs presenting 
processed HLA peptides derived from donor cells [15,16]. 
3. The semi-direct pathway of antigen presentation refers to a combination of direct and 
indirect pathways [16-18].  
Unless the immune system is modulated by immunosuppressants, recognition of foreign HLA 
molecules or ABO blood-group antigens will lead to rejection of the transplanted organ. 
Depending on the immunological mechanism and the time of presentation, the process is 
often referred to as hyperacute, acute or chronic rejection (Figure 2 Section 1.3) [14,19]. 
1.2.3.1 Hyperacute rejection 
Hyperacute rejection occurs within minutes to hours post transplant and is caused by 
preexisting alloreactive antibodies of the patient mediating damage to the graft. This type of 
rejection is due to genetic differences between donor and recipient ABO blood-group antigens 
and to lesser extent, HLA molecules. Preexisting host antibodies in the blood will 
immediately react with antigens from the donor organ and activate the complement system 
leading to cell death, local coagulation and irreversible rejection of the organ. However, 
because donor-recipient crossmatch testing is performed pre Tx, hyperacute rejection is rarely 
seen [14]. 
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1.2.3.2 Acute rejection  
Acute rejection may occur at any time post-operatively, but is most frequent within the first 
days and up to 6 months post Tx. Acute rejection can be mediated by lymphocytes (cellular) 
and/or circulating antibodies (humoral). Furthermore, unlike hyperacute rejection, acute 
rejection may be prevented with immunosuppressive therapy [14,20]. 
1.2.3.3 Chronic allograft injury 
Chronic allograft injury occurs several months up to years after Tx. The reaction is 
characterized by slow deterioration of graft function with the development of tubular atrophy 
and interstitial fibrosis [14,20,21]. 
 
 
1.3 Immunosuppressive therapy 
After allo-Tx, lifelong immunosuppression is required to prevent rejection of the graft and 
maintain long-term allograft survival (Figure 2). The immunosuppression therapy usually 
consists of a combination of drugs (Figure 3) with different mechanisms of action. This 
provides additive or synergistic immunosuppression while minimizing the toxicity of each 
drug [22,23].  
Since the introduction of combined azathioprine and glucocorticoid therapy approximately 
50 years ago, there has been a remarkable improvement in the immunosuppressive therapy. 
Over the previous years, several potent immunosuppressive agents aim to diminish toxic side 
effects which lead to the improvement of the patients’ quality of life.  
Allograft recipients treated with lifelong immunosuppressive drugs have an increased risk of 
drug toxicity, infections and malignancies. This may have negative impact on long-term 
allograft and patient survival after Tx [14]. To achieve the right balance of 
immunosuppression, the combination of immunosuppressive agents is kept to the lowest 
effective doses. The initial post transplant period is associated with the highest risk of acute 
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allograft rejection. Thus, obtaining a sufficient degree of immunosuppression is particular 
important during the first weeks after Tx.  
The choice of immunosuppressive regimen depends on various clinical factors and the type of 
organ transplant [24]. At Rikshospitalet, the standard maintenance drug regimen currently 
consists of a calcineurin inhibitor (CNI: cyclosporine or tacrolimus), prednisolone and 
mycophenolic acid. In addition, methylprednisolone (250 mg) and the interleukin 2 receptor 
(IL2R) monoclonal antibody basiliximab are given intravenously on the day of surgery and at 
day 4 post Tx (basiliximab only). In renal transplant recipients, the CNI of choice is 
tacrolimus (Tac), except in patients with impaired glucose tolerance who will receive 
cyclosporine (CsA). Furthermore, the CNIs are frequently replaced or administered in 
reduced doses in combination with a mechanistic target of rapamycin (mTOR) inhibitor, 
sirolimus or everolimus, in patients with an increased risk of CNI toxicity or malignancies 
[25].  
 
Early acute rejection Late rejection Chronic allograft injury
Early intense therapy Lower dose therapyInduction therapy
Maintenance immunosuppression
Days Weeks Months Years
Tx
 
 
Figure 2: Risk of rejection and immunosuppressive dose regimens during different phases of post 
transplantation (Tx). 
___________________________________________________________________________ 
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Figure 3: Molecular structure of immunosuppressive drugs used after solid organ transplantation. 
___________________________________________________________________________ 
 
1.3.1 Calcineurin inhibitors (CNIs) 
The two CNIs, CsA and Tac, are not structurally related (Figure 3) but have similar 
mechanisms of action. 
The principal action of CNIs is the inhibition of the phosphatase calcineurin, which is a key 
component of T cell activation. CsA and Tac bind to the immunophilins cyclophilin and 
FK-506-binding protein (FKBP), respectively, in the cytoplasm (Figure 4). These complexes 
block the phosphatase activity of calcineurin and inhibit the dephosphorylation of the 
transcription factor NFAT. This prevents the translocation of the transcription factor into the 
nucleus and thereby inhibits the transcription of several proinflammatory cytokine genes 
including IL2, IL3, IL5, colony stimulating factor 2 (granulocyte-monocyte) (CSF2), 
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interferon gamma (IFNG) and tumor necrosis factor-alpha (TNF-α). The NFAT-regulated 
cytokines play an important role in the initiation of immune responses and inhibition of these 
cytokines prevents T cell activation and proliferation (Figure 4). 
Both CsA and Tac have an excellent efficacy profile with low acute rejection rates [26]. 
Several studies have reported similar patient and graft survival after renal Tx with CsA and 
Tac based immunosuppression [27,28]. However, Tac has been associated with a reduced 
incidence of acute rejection episodes [29-36]. 
 
NFAT
P
NFAT
NFAT
Calcineurin
IL2, IFNG, CSF2
Activation
Proliferation
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Cyclophilin
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Activation
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P
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A B
 
 
Figure 4: The effect of calcineurin inhibitors in lymphocytes. A: Stimulation of the T cell receptor and 
costimulatory receptors results in increased calcineurin activity, dephosphorylation of the nuclear factor of 
activated T cells (NFAT), increased transcription of cytokines and finally lymphocyte activation and 
proliferation. B: After binding to immunophilins, cyclosporine (CsA) and tacrolimus (Tac) inhibit calcineurin 
activity and finally the transcription of NFAT-regulated cytokines and cell proliferation.  
APC; Antigen-presenting cell, CSF2; colony stimulating factor 2 (granulocyte-monocyte), FKBP12; 
FK-506-binding protein 12, IFNG; interferon-gamma, IL2; interleukin 2 
___________________________________________________________________________ 
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1.3.1.1 Cyclosporine (CsA) 
Since the introduction into clinical practice in 1978, CsA has revolutionized the field of solid 
organ Tx and has developed into the standard drug for preventing allograft rejection. Both 
patient and graft survival rates have significantly improved [37]. CsA is a lipophilic 
metabolite extracted from soil fungi like Tolypocladium inflatum and Cylindrocarpon 
lucidum. The mechanism of action is described in Section 1.3.1.  
CsA exhibits a wide inter- and intraindividual variability in pharmacokinetic (PK) profiles. 
Following oral administration, absorption of CsA is slow. The poor and variable 
bioavailability of the first CsA formulation, Sandimmune, led to the development of CsA 
microemulsion (CsA-ME: Neoral), presenting reduced variability in gastrointestinal 
absorption and 30% higher bioavailability [38-41].   
CsA is metabolized predominantly by cytochrome P450 (CYP), 3A4 enzymes, in the liver 
and intestine and is a substrate of the drug transporter P-glycoprotein (ABCB1). The primary 
pathway of metabolites elimination is through biliary excretion [42,43]. The mean elimination 
half-life ranges from 6 up to 20 hours. CsA is subject to numerous drug (e.g. azole antifungals 
and some macrolide anibiotics) and food (e.g. grapefruit) interactions that may increase or 
decrease CsA concentration in whole blood.  
Adverse effects associated with CsA include nephrotoxicity, hypertension, neurotoxicity, gum 
hypertrophy, hirsutism, post Tx diabetes mellitus, hyperlipidemia and hemolytic-uremic 
syndrome. The incidence of nephrotoxicity and diabetes has been related to drug exposure 
[35,44]. Although CsA and Tac share similar adverse effect profiles, the incidence of 
hypertension, dyslipidemia, gingival hyperplasia and hirsutism is reported to be higher with 
CsA [45]. 
 
1.3.1.2 Tacrolimus (Tac) 
CsA has been diminished over the last years while the use of Tac is increasing [35,46-48]. 
Tac is a macrolide immunosuppressant first isolated from Streptomyces tsukubaensis in 1984 
[49]. Although similar mechanisms of action (Section 1.3.1), Tac is 10 – 100 times more 
potent than CsA on a mg by mg basis [50]. Since 1994 Tac has been used clinically to prevent 
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allograft rejection in renal patients. Currently, oral Tac is available as immediate-release, 
twice-daily formulations (Prograf, Tacni, Modigraf) and a prolonged-release, once-daily 
formulation (Advagraf). Although the clinical efficiency is reported to be comparable, 
pharmacokinetics differ between the immediate- and prolonged-release formulations [43,51].  
As for CsA, the oral bioavailability of Tac is poor and highly variable, ranging 5 – 93% 
(mean 25%) [52,53]. Following oral administration of the immediate-release formulations, 
peak whole blood concentrations usually occur after 1 – 2 hours. The absorption is reduced in 
the presence of food. In blood, Tac is extensively distributed to erythrocytes and is 
approximately 99% protein-bound. Similar to CsA, Tac is a substrate of the drug efflux 
transporter P-glycoprotein (ABCB1) and is metabolized by CYP3A4 and CYP3A5 enzymes 
in the liver and intestine [54]. The metabolites are predominantly eliminated by biliary 
excretion and the elimination half-life of Tac is variable and ranges from 3.5 up to 40.5 hours 
[43,55]. As reported for CsA, Tac is also subject to range of drug and food interactions such 
as erythromycin, St. Johns Wort or grapefruit (Section 1.3.1.1). 
Nonimmune adverse effects of Tac are similar to those reported for CsA. However, Tac has 
been associated with a higher rate of new-onset diabetes mellitus and post Tx neurological 
side effects such as tremor, headache and sleep disturbances [35,56]. The side effects appear 
to be dose dependent and are usually reversible. However, the effect on renal function may 
persist.  
 
1.3.2 Glucocorticoids 
Glucocorticoids were the first immunosuppressive drugs used in Tx and they are still a part of 
first-line treatment for both prevention and treatment of acute allograft rejection [57].  
Glucocorticoids are non-specific agents with immunosuppressive effect on a wide variety of 
cells. At the cellular level, the majority of immunosuppressive effects are either directly or 
indirectly related to transcriptional effects on a variety of cytokines. Consequently, 
glucocorticoids inhibit a broad range of immune responses mediated by T cells, B cells and 
phagocytes.  
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Glucocorticoids have numerous well-known side effects such as impaired wound healing, 
increased risk of infection, hypertension, dyslipidemia, and glucose intolerance. These side 
effects contribute to the high prevalence of cardiovascular disease in transplant recipients 
[58]. 
 
1.3.3 Purine analogues and proliferation inhibitors  
Since the 1990s, mycophenolic acid has progressively replaced azathioprine in standard 
immunosuppressive protocols because of fewer side effects and a reduced risk of rejection 
[40,59-61]. Mycophenolic acid, a noncompetitive inhibitor of inosine monophosphate 
dehydrogenase (IMPDH), prevents DNA synthesis by blocking de novo purine synthesis in 
T and B cells and thereby inhibiting cell proliferation and function.  
Mycophenolic acid inhibits bone marrow function and may cause gastrointestinal adverse 
effects. Other side effects are associated with overimmunosuppression, especially a higher 
incidence and severity of cytomegalovirus (CMV) infections. However, mycophenolic acid is 
not considered to be nephrotoxic [58,62]. 
 
1.3.4 Interleukin 2 receptor antibody 
Basiliximab (Simulect) is a chimeric monoclonal antibody used for induction therapy. It is 
administered intravenously the day of Tx and 4 days post Tx. The drug binds to the CD25 
antigen on T cells and thereby prevents the binding of IL2 to its receptor (IL2R). 
Consequently, activation of T cells is inhibited [63]. The use of basiliximab has been reported 
to reduce the incidence of acute rejection in renal transplant recipients [64,65].  
 
1.3.5 Mechanistic target of rapamycin (mTOR) inhibitors 
Sirolimus, or rapamycin, is a macrolide antibiotic with a similar molecular structure to Tac. 
Sirolimus binds to the same immunophillin as Tac. Unlike the Tac complex, the sirolimus 
complex inhibits mTOR, a protein kinase essential for cell cycle progression and 
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proliferation. Thus, inhibition of mTOR prevents T cell proliferation. More recently, 
everolimus, a synthetic derivate of sirolimus, was introduced. Sirolimus and everolimus share 
the same molecular mechanism of action, but differ in pharmacokinetic characteristics [66]. 
Compared to CNIs, mTOR inhibitors are less effective in preventing rejection episodes. 
However, mTOR inhibitors may be beneficial in the context of CNI minimization or 
withdrawal and to reduce the risk of post Tx malignancies [67-70].  
The side effect profiles of sirolimus and everolimus are similar and include dose-dependent 
bone marrow toxicity, impaired wound healing, acne, mouth ulcers, abdominal pain, 
hyperlipidaemia, thrombocytopaenia and anaemia [58]. 
 
 
1.4 Individualization of CNI therapy 
Both CsA and Tac are characterized by a narrow therapeutic range and large inter- and 
intraindividual variability with respect to both PKs and pharmacodynamics (PD). This 
emphasizes the need for therapeutic drug monitoring (TDM) to optimize the 
immunosuppressive effect while minimizing toxicity. 
 
1.4.1 Therapeutic drug monitoring (TDM) 
The conventional TDM of CNIs involves the measurement of drug concentrations in whole 
blood (Figure 5). Individualization of CNI therapy based on concentration measurements is 
known to reduce the incidence of rejection episodes, CNI-specific toxicity and infections 
related to overimmunosuppression.  
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Figure 5: Therapeutic Drug Monitoring (TDM).  Individualization of drug therapy based on drug 
concentration measurements may improve clinical outcomes, especially of drugs with a narrow therapeutic 
range.  
___________________________________________________________________________ 
 
The area-under-the-blood-concentration-versus-time-curve (AUC) from 0 to 12 hours 
(AUC0-12h) is considered an optimal estimate of total CNI exposure since CNI AUC is 
associated with clinical endpoints. However, AUC0-12 measurements are impractical for 
clinical routine [71]. Currently, CNI therapy is usually monitored by measurement of trough 
concentrations (C0). However, C0 is not strictly correlated to AUC0-12h levels [72] and does 
not reflect the biologic effect of CNIs in an individual patient. Several studies have reported 
that C0 levels did not differentiate patients at risk of acute rejection or nephrotoxicity [73-75]. 
Compared to conventional monitoring, measurement of post dose concentrations has been 
reported to improve clinical outcomes during the first months of CsA therapy. Measurements 
of CNI concentrations at 1.5 (C1.5) or 2 (C2) hours post dose have been shown to be good 
predictors of Tac and CsA exposure, respectively [30,76,77]. Furthermore, measurement or 
estimation of the AUC0-12h by using two or three concentrations at the beginning of dose 
interval may better predict the clinical effect to CNIs [78].  
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1.4.2 Clinical outcomes of CNI therapy  
Over the last couple of decades, immunosuppressive therapy in Tx have improved 
significantly. The introduction of CsA and Tac has contributed to remarkable improvements 
of short-term outcomes. Currently, the 1 year patient and graft survival rates in renal Tx are 
approximately 90% [27].  
Importantly, the long-term allograft survival rates (>1 year post Tx) have not improved in 
parallel with the short-term outcomes. Morbidity and mortality remain much higher than in 
the general population, mainly due to the long-term complications [79,80]. Considering 
long-term outcomes, 36 – 50% of renal allografts are lost due to patient death related to 
cardiovascular diseases, infections or malignancies. The leading cause of late graft loss 
among surviving recipients is chronic allograft nephropathy with tubular atrophy and 
interstitial fibrosis, a common complication of long-term CNI therapy [81-84]. This suggests 
a potential for improving long-term outcomes after Tx by reducing adverse effects related to 
CNIs and to overimmunosuppression more generally. 
 
1.4.3 Pharmacodynamic monitoring of CNIs 
PD is the study of drug effects in the body. Compared to PK monitoring, measurement of 
molecular or cellular responses may provide a more direct estimation of clinical response of a 
drug. So far, PD monitoring of immunosuppressive drugs has not been implemented in 
clinical routine practice in Tx. However, PD monitoring of CNIs is currently investigated in 
many clinical studies [31,80].  
The PD effects of CNIs can be assessed with either direct (specific markers) or indirect 
(global markers) biomarkers [85]. A number of studies have investigated potential 
associations between clinical outcomes and PD biomarkers like intracellular IL2 
synthesis [86], intracellular calcineurin activity [87] or the expression of intracellular 
adenosine triphosphate production in CD4+ cells after phytohemaglutinin (PHA) stimulation 
[88,89]. So far, the most promising strategy seems to be the measurement of NFAT-regulated 
gene expression [77,80]. Several studies in different patient cohorts have reported an 
association between NFAT-regulated gene expression levels and clinical outcomes like acute 
rejection episodes, infections and malignancy after Tx [56,90-92]. This supports a potential 
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for monitoring NFAT-regulated gene expression, in combination with PK monitoring, to 
individualize and improve CNI therapy in solid organ recipients. 
 
 
1.5 Immune activation assay 
In resting lymphocytes, the expression levels of NFAT-regulated genes in whole blood are 
very low. Ex vivo activation of lymphocytes imitates the immune activation of lymphocytes in 
vivo, e.g. in response to a foreign organ, and thereby provides an estimate of the immune 
activation potential of an individual.  
PHA, phorbol 12-myristate 13-acetate (PMA) and ionomycin are common stimulants utilized 
in a variety of immunologic assays. PHA results in cell agglutination and activates T cells by 
interacting with T cell receptor complex [93,94]. The combination of PMA and ionomycin 
activates protein kinase C and increases intracellular calcium levels, which in turn results in 
T cell activation [95].  
 
 
1.6 Gene expression analysis 
1.6.1 RNA isolation 
The quality and quantity of starting nucleic acids is critical for gene expression analysis. 
Whole blood contains relatively small amounts of mRNA and high levels of ribonucleases 
(RNase). Thus, special precautions are required before, during and after RNA isolation to 
avoid RNA degradation by RNases or unintended regulation of gene expression. RNA 
isolation relies on good laboratory technique and RNase-free techniques. Furthermore, RNA 
isolation protocols include strong denaturants to inhibit endogenous RNases. Several different 
techniques and protocols are available for isolation of RNA including organic extraction 
methods, spin basket formats, magnetic particle methods, and direct lysis methods. The 
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optimal technique may differ depending on the type of sample material, sample volume and 
number of samples. 
 
1.6.2 Reverse transcription PCR  
The number of individual mRNA molecules in a sample is very low and quantification of 
mRNA levels depends on the use of sensitive methods. Reverse transcription (RT) followed 
by real-time PCR constitutes a sensitive analysis method which is increasingly used for gene 
expression measurements. The procedure starts with the conversion of RNA into cDNA, 
which in turn serves as template in amplification reactions. The procedure can be performed 
as one- or two-step processes. In one-step RT, the RT and PCR reactions are performed in the 
same tube, which limits sample handling and thereby reduces the risk for pipetting errors and 
contamination. The two-step procedure allows separate optimization of the RT and PCR 
steps, which in turn may improve the sensitivity and precision of the assay. Furthermore, a 
two-step approach is useful for detecting multiple mRNAs from a single RNA sample.     
Different strategies can be used to prime the cDNA synthesis:   
1. Oligo(dT) primers bind to the poly(A)tail of mRNA molecules. This strategy may 
favour synthesis of full-length cDNA, however, cDNA synthesis efficiency may differ 
throughout the length of the mRNA.  
2. Random hexamer primers bind to many sites throughout the length of an RNA. The 
priming strategy is independent on the presence of a poly(A)tail (e.g. tRNA, rRNA).  
3. Sequence-specific primers bind to specific target sequences and are always used in 
one-step RT-PCR.  
 
1.6.3 Real-time quantitative PCR  
Real-time quantitative PCR (qPCR) involves monitoring of amplification products in each 
PCR cycle using fluorescent dyes.  
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1.6.3.1 PCR 
PCR has evolved far beyond simple amplification to an extremely useful technique, which is 
implemented in a variety of research fields and diagnostic assays.  
Using PCR, specific DNA sequences can be copied or “amplified” many 
thousands-to-millions fold. In addition to a template sequence, the necessary reagents are 
specific primers, DNA polymerase, Mg2+ and nucleotides. The DNA polymerase requires a 
small area of double-stranded DNA and Mg2+ as a cofactor to initiate DNA replication. Thus, 
the amplified sequence depends on the sequence of the primers. 
The PCR technique is based on thermal cycling. A PCR program usually consists of 20 – 50 
cycles, where each cycle comprises (2–) 3 different temperature steps.  
1. Denaturation at 94 – 98°C: During this step, double-stranded DNA will denature to 
single-stranded DNA. 
2. Annealing at 50 – 65°C: Primers hybridize to the sense and antisense strands of the 
DNA template. The annealing temperature is a critical parameter affecting the efficacy 
and specificity of the PCR. The melting temperature
 
of the primers depends on the 
length and base composition of the oligonucleotides.  
3. Extension/elongation at 72°C: The elongation temperature is the ideal working 
temperature for the DNA polymerase. The most frequently used is the heat stable 
bacterial DNA polymerase Taq (Thermus aquaticus). Starting at the primer, DNA 
polymerase generates complementary copies by incorporating nucleotides that are 
complementary to the target template.  
The next cycle of PCR is then ready to start over. 
Theoretically, the amount of product is doubled in each cycle of PCR as illustrated in 
Figure 6.  
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Figure 6: Exponential amplification of a specific DNA sequence by PCR. After n cycles, the number of DNA 
copies is 2n. 
___________________________________________________________________________ 
 
1.6.3.2 Detection formats 
The fluorescent signal generated during real-time PCR is directly proportional to the amount 
of PCR product present. Several different fluorescent reporters are available for real-time 
PCR, and each has specific assay design requirements. The detection formats can be divided 
into sequence-independent and sequence-specific. 
 
Sequence-independent detection formats 
Sequence-independent detection formats include intercalating dyes such as SYBR Green I, 
and detect all double-stranded DNA. The format cannot discriminate between specific PCR 
products, non-specific products and primer dimers. SYBR Green I emits very little 
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fluorescence when it is free in solution. However, once bound to double-stranded DNA, the 
fluorescence intensity increases about 100 fold (Figure 7) [96,97]. The sequence-independent 
detection formats are inexpensive, easy to use and allow sensitive detection of different target 
sequences. The ability to bind to all dsDNA molecules can be exploited to detect non-specific 
products or primer dimers by performing a melt curve analysis (see Section 1.6.7.1 for further 
details).  
 
A BSYBR Green I
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Figure 7: SYBR Green I-based detection. A: SYBR Green I fluorescence emission is low when free in 
solution with denatured DNA and primers. B: Binding of SYBR Green I to double-stranded DNA generates 
much higher fluorescence (100 fold). 
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Sequence-specific detection formats 
Sequence-specific detection formats imply that the fluorescence signal will only increase if 
the probe is bound to a specific DNA sequence. The formats include fluorophore-labeled 
probes like hydrolysis probes, simpleProbe and hybridization probes.  
Hydrolysis (TaqMan) probes are oligonucleotides with a fluorescence reporter and a quencher 
dye attached. During PCR, the probe is cleaved by the 5´→ 3´-nuclease activity of the DNA 
polymerase, separating the reporter and quencher dyes. This generates a fluorescent signal 
that increases with each cycle, proportional to the rate of probe cleavage.  
SimpleProbe probes are oligonucleotides labeled with a single fluorophore. Once bound to the 
complementary target sequence, the fluorescence increases due to a conformational change. 
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Hybridization probes are a pair of sequence-specific oligonucleotides that hybridizes side by 
side on the PCR product. The 3’ end of the upstream probe is labeled with fluorescein, which 
acts as a fluorescence resonance energy transfer (FRET) donor, while the 5’ end of the 
downstream probe is labeled with an acceptor dye. When both probes are bound to their 
complementary target sequence the dyes will be in close proximity to each other, allowing 
FRET from the donor to the acceptor fluorophore (Figure 8). Finally, the acceptor fluorophore 
emits fluorescent light with a different wavelength.  
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Figure 8: Hybridization probe-based detection. A: Hybridization probes include a donor probe labeled with 
fluorescein in the 3´end and an acceptor probe labeled with an acceptor dye in the 5´end. The donor dye is 
excited by blue light and emits green fluorescent light. B: Binding of the hybridization probes to their specific 
complementary regions results in fluorescence resonance energy transfer (FRET) from the donor to the acceptor 
probe and finally emission of fluorescence with a different wavelength. 
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1.6.3.3 Primer and probe design 
Successful qPCR requires good primer design. Primers should bind selectively to the target 
sequence. For adequate selectivity, the primers should ideally comprise 18 – 30 base pairs and 
have GC content in the range of 40 – 60%. There are several software tools available for 
oligonucleotide design and evaluation of primer and probe sequences (Table 4). Primer and 
probe design is further described in Section 4.4.  
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1.6.4 Relative mRNA quantification 
Gene expression levels may be determined by absolute or relative real-time PCR 
quantification strategies (Figure 17 Section 4.6). Absolute quantification depends on 
calibration curves to relate PCR signals to input copy number. In contrast, relative 
quantification determines the change in target mRNA expression levels relative to the level of 
reference mRNA, e.g. mRNA of one or more endogenous “housekeeping” genes. The 
calculation of relative gene expression is based on the cycle number where the fluorescence 
rises above background (begins its exponential phase), defined as the crossing point (Cp) 
(Figure 9). The Cp is inversely proportional to the initial cDNA template concentration.  
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Figure 9: Amplification curves. The data generated by real-time fluorescence monitoring during PCR result in 
amplification plots. The crossing point (Cp) is the cycle number where the fluorescence rises above background. 
The figure illustrates the amplification curves of two samples with different initial template concentrations. A 
higher Cp value represents a lower initial concentration. 
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1.6.4.1 Reference genes 
Reliable quantification of relative gene expression levels depends on normalization to a fixed 
reference. The reference genes should correct for sample-to-sample variation, differences in 
initial amount, isolation yields, RNA/DNA degradation, RNA/DNA quality, pipetting and 
cDNA synthesis efficiency. Furthermore, the reference genes may also identify the presence 
of PCR inhibitors. Reference genes are usually genes encoding endogenous products that are 
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essential for normal cell function. Several studies have documented that there is no single 
reference gene with constant expression levels across different sample materials and 
experimental conditions [98-100]. Thus, it is generally recommended to normalize the 
expression of target genes to a reference gene index based on several reference genes [101]. 
Furthermore, to reduce the probability of co-regulation, the reference genes should preferably 
belong to different functional classes.   
1.6.4.2 PCR-efficiency correction  
In theory, the number of PCR products doubles at each cycle if the PCR-efficacy is 100%    
(E = 2, Equation 1A). However, in practice, the efficiency is often less than 100% 
(Equation 1B) because of PCR inhibitors like heparin, hemoglobin, myoglobin, lipids, 
polysaccharides, amount and quality of RNA/DNA, non-specific products, cycle conditions 
and PCR reagents and equipment [102-104]. The samples may be affected to different extent. 
Various strategies have been established to normalize these variations (see methods). 
  
NCp= N0 x ECpNCp = N0 x 2Cp
A B
 
Equation 1: The basic equation describing PCR. A: PCR-efficiency is assumed to be 100%. B: The actual 
PCR-efficiency is included in the calculation. 
Cp; crossing point, NCp; number of molecules at Cp, N0; initial number of molecules, n; number of PCR cycles 
performed, E; PCR-efficiency  
___________________________________________________________________________ 
 
Different approaches have been reported to estimate the actual efficiency of the real-time 
PCR. The standard curve approach is based on the amplification of serial dilutions of cDNA 
and construction of standard curves by plotting Cp values against the log of initial template 
concentrations (Section 4.5.4). Based on the slope of the standard curve, PCR-efficiency is 
estimated according to Equation 2, Section 4.5.4. A slope of -3,337 indicates a 
PCR-efficiency of 100% (E = 2). 
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1.6.5 Optimization of PCR conditions and assay validation  
In addition to the selection of suitable primers and probes, it is necessary to optimize and 
validate the final assays. 
1.6.5.1 SYBR Green I analysis 
Melting curve analysis with SYBR Green I is a fast and sensitive method to evaluate the 
selectivity of the primers.  
Intercalating dyes like SYBR Green I allows real-time PCR-products to be directly evaluated 
by melting curve analysis. Initially, double-stranded DNA amplicons give high levels of 
fluorescence. As the temperature gradually increases double-stranded DNA melts into 
single-stranded DNA. A typical plot of the dissociation curve is shown in Figure 10A. In 
Figure 10B, the intensity of fluorescence is plotted against temperature and then the -∆F/-∆T 
(change in fluorescence/change in temperature, y-axis) is plotted against temperature (x-axis). 
The melting temperature of a PCR product depends on the length and GC content of the 
DNA. Non-specific PCR-products and primer dimers usually present melting temperatures 
significantly different from the specific product and are easily detected.   
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Figure 10: SYBR Green I-based melting curve analysis. A: Raw melting curve profiles using SYBR Green I 
as a fluorescent dye. B: Negative first derivative melting curve plots using SYBR Green I as a fluorescent dye. 
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1.6.5.2 Agarose gel electrophoresis 
Gel electrophoresis is a technique used to separate the products based on molecular size and 
charge. As DNA is negatively charged due to phosphate groups in the backbone of DNA, it 
will migrate towards the positive electrode (anode).   
The electrophoretic distance of DNA molecules through agarose gels is also dependent on 
their size, the composition of the buffer, the length of the electrophoresis, the properties of the 
gel, and the amount of current applied. The number of base pairs of a PCR product determines 
the size of the molecule. When traveling horizontally through an agarose gel, large molecules 
will migrate slower through the pores of the gel than small molecules. Following gel 
electrophoresis, DNA bands can be visualized in gels using intercalating dyes, such as 
ethidium bromide. Finally, the bands of the PCR-products are compared with the bands of a 
molecular weight marker including DNA fragments of known size.   
1.6.5.3 DNA sequencing 
The actual sequence of PCR-products may be determined by DNA sequencing. Currently, 
several sequencing strategies are available. The chain terminator method or Sanger dideoxy 
method relies on base-specific chain termination after incorporation of dideoxynucleotides 
(ddNTPs). At each step of chain extension, the DNA polymerase adds either a 
deoxynucleotide or the corresponding ddNTP. The ddNTPs are nucleotide base analogs that 
lack the 3′-hydroxyl group required for the formation of phosphodiester bonds. The four 
ddNTP (ddA, ddC, ddG and ddT) are labeled with different fluorescent molecules. This 
results in the formation of products of various lengths. Finally, the products are separated by 
capillary electrophoresis and characterized by fluorescence measurements. 
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2 Goals of the project  
Following organ Tx, lifelong immunosuppressive therapy is needed to prevent rejection of the 
transplanted organ. Currently, CNIs represent the cornerstone in most immunosuppressive 
regimens. Despite contributing to remarkable improvements in short-term outcomes, CNIs 
may have negative impact on long-term outcomes post Tx. Due to the narrow therapeutic 
range and PK variability of CNIs, dosing is usually guided by PK measurements. 
Furthermore, PD monitoring may provide a more direct estimation of the CNI response and 
thereby allow further optimization of CNI therapy.  
The main goal of the project is to investigate NFAT-regulated gene expression as a potential 
PD biomarker of CNI response in renal transplant recipients.  
The sub-goals are: 
1. To establish and validate a real-time PCR assay for the quantification of 
NFAT-regulated gene expression in whole blood samples. 
2. To assess the effect of ex vivo exposure to different immunosuppressive drugs and 
concentrations on NFAT-regulated gene expression.   
3. To investigate the NFAT-regulated gene expression in clinical samples from renal 
allograft recipients treated with Tac. 
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3 Materials  
The reagents and equipment used in this project are listed in Table 1 and Table 2, 
respectively. In addition, centrifuge, vortex mixer, pipettes and filter tips were used.  
 
Table 1: Reagents 
Reagents Vendor/ Producer Cat. No. 
BigDye Terminator v3.1 
Cycle Sequencing Kit 
Applied Biosystems, Foster 
City, California, USA 4 336 917 
Bromophenol blue Sigma-Aldrich Norway AS, Oslo, Norway B-6131 
Dithiothreitol (DTT), 10 g Roche Diagnostics GmbH, Mannheim, Germany 10 708 984001 
DNA-molecular Weight 
marker V 
Roche Diagnostics GmbH, 
Mannheim, Germany 10 821 705 001 
DNA ZAP ™ I and II Ambion/Applied Biosystems, Austin, TX, USA AM9890 
ExoSAP-IT Amersham Biosystems, Foster City, California, USA US 77705 
Ionomycin calcium salt  Sigma-Aldrich Norway AS, Oslo, Norway I 3909 
Lectin from Phasesous 
vulgaris  
Sigma-Aldrich Norway AS, 
Oslo, Norway L 4144 
LightCycler® 480 SYBR 
Green I Master 
Roche Diagnostics GmbH, 
Mannheim, Germany 4 707 516 001 
LightCycler® 480 Probes 
Master 
Roche Diagnostics GmbH, 
Mannheim, Germany 4 707 494 001 
Lysis/Binding Buffer with 
guanidinium thiocyanate  
Roche Diagnostics GmbH, 
Mannheim, Germany 3 542 394 001 
MagNA Pure LC DNA 
Isolation Kit-High 
Performance kit  
Roche Applied Science, 
Penzberg, Germany 3 542 394 001 
MS2 RNA Roche Diagnostics GmbH, Mannheim, Germany  10 165 948 001 
Primers and hybridization 
probes (sequences are given 
in Table 5) 
TIB® MOLBIOL, Berlin, 
Germany (synthesis according 
to user’s design) 
  
Phorbol 12-myristate 13-
acetate 
Sigma-Aldrich Norway AS, 
Oslo, Norway P 1585 
Red Blood Cell Lysis Buffer, 
100 mL 
Roche Diagnostics GmbH, 
Mannheim, Germany 11 814 389 001  
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Reliant Gel system 4% 
Nusieve 3:1 Plus Agarose, 8 
well 
Lonza BioScience Rockland, 
ME, USA 54927 
RPMI 1640 medium with L-
glutamine  
Sigma-Aldrich Norway AS, 
Oslo, Norway R 8758 
TE-buffer 1X, Molecular 
Biology Grade 
Promega Corporation, 
Madison, WI, USA V 6231 
Transcriptor First Strand 
cDNA Synthesis Kit 
Roche Diagnostics GmbH, 
Mannheim, Germany  4 897 030 001 
TBE-Buffer 10X Bio-Rad Laboratories, Inc., Hercules, California, USA 161-0733 
 
 
Table 2: Equipment  
Equipment Vendor/ Producer Cat. No. 
ABI PRISM® 3100 Genetic 
Analyzer 
Carlsbad, California, USA  Laboratory supplier 
Applied Biosystems 2720 
Thermal Cycler 
 Applied Biosystems, Foster 
City, California, USA 
Laboratory supplier 
Biorad Molecular Imager 
GelDoc TM XR  
Bio-Rad Laboratories, Inc., 
Hercules, California, USA 
Laboratory supplier 
Sodium-Heparin tubes, 6 mL Greiner Bio One, GmbH Bad 
Haller, Kremsmunster Austria 
456051 
LightCycler® 480 instrument Roche Applied Science, 
Mannheim, Germany 
Laboratory supplier 
LightCycler® 480 Multiwell 
Plate 96 
Roche Applied Science, 
Mannheim, Germany 
4 729 692 001 
LightCycler® 480 Sealing 
Foil 
Roche Applied Science, 
Mannheim, Germany 
4 729 757 001 
MagNA Pure LC TM 2.0 
instrument 
Roche Applied Science, 
Mannheim, Germany 
12 236 931 001 
MagNA Pure LC Cartridge 
Seal 
Roche Applied Science, 
Mannheim, Germany 
03 118 827 001 
MagNA Pure LC Cooling 
Block, LC Centrifuge 
Adapters  
Roche Applied Science, 
Mannheim, Germany 
12 190 664 001 
MagNA Pure LC Cooling 
Block, 96 well PCR Plate 
Roche Applied Science, 
Mannheim, Germany 
12 189 674 001 
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MagNA Pure LC Greasing 
Set 
Roche Applied Science, 
Mannheim, Germany 
3 561 402 001 
MagNA Pure LC Processing 
Cartridges 
Roche Applied Science, 
Mannheim, Germany 
3 004 147 001 
MagNA Pure LC Reactions 
Tips large 
Roche Applied Science, 
Mannheim, Germany 
03 004 171 001 
MagNA Pure LC Reactions 
Tips small 
Roche Applied Science, 
Mannheim, Germany 
03 004 180 001 
MagNA Pure LC Reactions 
Tub 20 medium 
Roche Applied Science, 
Mannheim, Germany 
03 004 058 001 
MagNA Pure LC Reactions 
Tub 30 medium 
Roche Applied Science, 
Mannheim, Germany 
3 045 501 
MagNA Pure LC Reactions 
Tub large 
Roche Applied Science, 
Mannheim, Germany 
03 004 040 001 
MagNA Pure LC Sample 
Cartridges 
Roche Applied Science, 
Mannheim, Germany 
3 004 112 001 
MagNA Pure LC Tip Stands Roche Applied Science, 
Mannheim, Germany 
3 004 155 001 
MagNA Pure LC Tub Lids 
small medium 
Roche Applied Science, 
Mannheim, Germany 
03 004 082 001 
MagNA Pure LC Tub Lids 
large 
Roche Applied Science, 
Mannheim, Germany 
03 004 074 001 
MagNA Pure LC Waste Bag Roche Applied Science, 
Mannheim, Germany 
3 004 201 001 
Microtubes 1.5 Sarstedt, AC, Numbrecht 
Germany 
S 044 523 
Multiply®-Pro cup 0,2 ml AC, Numbrecht Germany S 044080 43/14 
Nanodrop® ND-1000 
Spectrophotometer 
Saveen Werner, Thermo 
Fisher Scientific, Wilmington, 
USA 
ND 1000 
Tube-strip Picofuge® Stratagene, Medcompare 
Diagnostics, California, USA 
Laboratory supplier 
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3.1 Blood samples for assay development and 
validation 
Assay development was based on blood samples from three healthy volunteers. Whole blood 
was drawn in heparinized blood tubes on repeated occasions. The assay validation also 
included pre dose and 1.5 hours post dose samples from a renal transplant recipient treated 
with Tac. The following sample processing steps are described in Section 4.1. 
 
 
3.2 MarkIt pilot study  
Five renal transplant recipients were enrolled in the MarkIt pilot study at Oslo University 
Hospital, Rikshospitalet, from February to March 2012. The study is still ongoing and the 
planned enrollment is a total of 30 patients. Inclusion criteria were renal Tx with a graft from 
a living donor and recipient age above 18 years. Patients were excluded if there were any 
medical limitations of blood sampling. The patients received immunosuppression according 
to the relevant protocol for renal Tx. Standard quadruple therapy consists of basiliximab, Tac, 
glucocorticoids and mycophenolic acid. The study was approved by the Regional Committee 
for Medical and Health Research Ethics in Norway. Informed consent was obtained from all 
study participants and they were free to withdraw from the study at any time.  
 
3.2.1 Samples from renal transplant recipients 
For the measurement of NFAT-regulated gene expression, whole blood was drawn in a 
heparinized tube (6 mL) on the following occasions:  
1. Once at 0 – 4 days before Tx and initiation of immunosuppressive therapy 
2. Pre dose and at 1.5 hours after Tac dosing on one day within 6 – 9 days post transplant 
3. Pre dose and at 1.5 hours after Tac dosing on one day within 5 – 7 weeks post 
transplant 
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4. Additionally, blood samples will be drawn pre and post dosing approximately 1 year 
post transplant. 
In parallel with the NFAT-regulated gene expression materials, whole blood was also 
sampled in ethylenediaminetetraacetic acid (EDTA) tubes (Vacuette®, Greiner Bio One) and 
PAXgeneTM Blood RNA tubes (PreAnalytix®, Qiagen) for the measurement of drug 
concentrations and assessment of potential mRNA biomarkers in other ongoing projects.  
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4 Methods  
Good laboratory practice is essential in order to achieve reliable results of gene expression 
(Figure 11). RNA is susceptible to degradation by RNases. To prevent contamination and 
establish an RNase-free environment, the instruments were decontaminated with UV-light, 
70% ethanol and DNA ZapTM before and after use. Pre-PCR, PCR and post-PCR operations 
were physically separated to prevent contamination with PCR products. Furthermore, 
protective disposable gloves and laboratory coats were worn at all times when handling 
reagents and sample materials. Reagents were of PCR quality and disposable plastic 
equipments were sterile and RNase-free. To avoid or minimize unintentional gene expression 
regulation ex vivo, RNA was preferably stabilized as soon as possible after blood collection.  
For quality controls, one negative control for each target gene was included per LightCycler 
96-well PCR plates. Negative controls contained all PCR reagents except the cDNA template 
which was replaced by water. This allowed detection of potential contamination of the PCR 
reagents.   
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Figure 11: Overview of the steps of nuclear factor of activated T cells (NFAT)-regulated gene expression 
assay.  
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4.1 Lymphocyte activation and sample 
preparation 
Lymphocytes were activated ex vivo within 2 hours after blood sampling (Section 3.1 and 
3.2.1). Pre and post dose samples were activated simultaneously. 
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Three different lymphocyte activation principles and different sample preparation procedures 
were compared by real-time PCR analysis of IL2, IFNG and CSF2 gene expression levels. 
The lymphocyte activation media consisted of complete RPMI 1640 medium with 
PHA (10 mg/L) alone, PMA (100 µg/L) in combination with ionomycin (5 mg/L) or all three 
agents together (PHA + PMA + ionomycin). The mitogen concentrations were based on 
previous studies [105]. Each of the three activation media, as well as a control medium 
without mitogens, was added to equal volumes of whole blood in 5 mL, Falcon/BD tubes. The 
mixture was incubated at 37°C for 0, 3, 24, 48 and 72 hours.  
Two different procedures were compared for sample preparation after ex vivo incubation of 
whole blood with mitogens. A two-step approach involved removal of red blood cells using 
the Red Blood Cell Lysis Buffer before lysis of leukocytes by addition of 
Lysis/Binding-buffer (LBB) with 1% (w/v) dithiothreitol (DTT). A simplified procedure 
involved cell lysis in a single step by adding LBB directly to the whole blood cell suspension. 
After optimization, the sample preparation of the final assay involved incubation of 150 µL 
whole blood with 150 µL activation medium containing PMA and ionomycin in Falcon/BD 
5 mL tubes. In addition, unstimulated controls were prepared by incubation of whole blood 
with medium without mitogens. The tubes were gently mixed and incubated for 3 hours at 
37°C, 5% CO2 and 95% humidity. After incubation, 200 µL cell suspension was transferred to 
1.5 mL Sarstedt microtubes, lysed with 700 µL LBB with 1% (w/v) DTT by vortexing for 
30 sec. The tubes were then frozen at −70°C until further preparations. 
 
 
4.2 Isolation of total RNA 
After thawing, cell lysates were mixed and transferred into MagNA Pure Sample Cartridges. 
Total RNA was isolated on the MagNA Pure LC instrument, using MagNA Pure LC RNA 
Isolation Kit-High Performance kit and the RNA HP external lysis protocol according to the 
manufacturer’s instructions. The total RNA isolation procedure included cell lysis with LBB 
and digestion of remaining proteins with Proteinase K. Released RNA was bound to the silica 
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surface of Magnetic Glass Particles due to the chaotropic salt conditions, isopropanol and the 
high ionic strength of the LBB. DNA was removed by DNase treatment and furthermore, 
followed by additional washing steps. The RNA was magnetically separated from the residual 
sample materials and finally, purified total RNA was eluted from the silica particles at 70°C.  
The initial sample and elution volumes were set to 800 µL and 50 µL, respectively. Total 
RNA was stored at –70°C until further preparations. 
 
 
4.3 Two-step reverse transcription and 
quantitative PCR  
Gene expression of IL2, IFNG and CSF2 was analyzed using RT-qPCR on the 
LightCycler® 480 instrument. An overview of the assay workflow is illustrated in Figure 12.  
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Figure 12: Workflow of nuclear factor of activated T cells (NFAT)-regulated gene expression assay.  
RT; reverse transcription 
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4.3.1 Reverse transcription (RT) 
The RNA was reverse transcribed into cDNA using Transcriptor First Strand cDNA Synthesis 
Kit according to the manufacturer’s protocol. The cDNA synthesis was primed by a 
combination of random hexamer and anchored-oligo(dT)18 primers. MS2 RNA (final 
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concentration of 10 µg/mL) was included as carrier RNA to stabilize RNA template and 
reduce the binding of RNA to microtubes and pipette tips. The RT reaction was performed in 
a final volume of 20 µL per reaction in 0.2 mL thin-walled PCR tubes using a thermal block 
cycler with a heated lid. The RT procedure, including thermal cycler program and reaction 
components, is summarized in Table 3.  
 
Table 3: Reverse transcription procedure  
Step Temperature 
(°C) 
Time 
(minutes) 
Reagents 
(volume/reaction) 
Comments 
1 65 5 Total RNA (5 µL) 
 
Water (PCR-grade) with MS2 
RNA (5 µL) 
 
Random hexamer primers  
(1 µL) 
 
Anchored-oligo(dT)18primer 
(2 µL) 
Denaturation of RNA 
secondary structures 
 
After 5 min incubation, 
PCR tubes were 
immediately placed on ice 
to prevent reformation of 
RNA secondary structures. 
This allows primer binding 
to the RNA templates 
2 25 10 Master mix of: 
 
Transcriptor Reverse 
Transcriptase Reaction Buffer 
(4 µL) 
 
Protector RNase inhibitor  
(0.5 µL) 
 
Deoxynucleotide Mix (2 µL) 
 
Transcriptor Reverse 
Transcriptase (0.5 µL) 
Binding of primers and 
initiation of cDNA 
synthesis  
3 Gradual increase of the temperature from 25 to 55°C.  
Slope +30, 0.3°C/sec 
 
4 55 30   cDNA synthesis 
5 60 5   cDNA synthesis at 
increased temperature to 
overcome potential RNA 
secondary structure 
6 85 5   Inactivation of the 
Transcriptor Reverse 
Transcriptase enzyme  
7 4 “Forever”   The reaction mixture is 
cooled to 4°C 
8 End  
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The products from two parallel cDNA synthesis reactions, 20 µL each, were mixed and 
diluted with PCR-grade water containing MS2 RNA to a final volume of 150 µL. 
(40 µL cDNA + 110 µL water with MS2 RNA). This provided suitable template 
concentrations and enough cDNA to perform approximately 30 PCR reactions. cDNA was 
stored at −20°C until PCR analysis.  
A calibrator sample was prepared by generating a pool of cDNA from activated lymphocytes 
(Sections 4.1, 4.2 and 4.3.1), aliquoted (1000 and 150 µL aliquots) and stored at −70°C and 
−20°C (Figure 13). 
 
Aliquots of calibrator
cDNA to keep in freezer
at -20°C and -70 °C
cDNA of different
samples
Mix of cDNA samples
 
 
Figure 13: Preparation of cDNA calibrator. cDNA were pooled from samples of three healthy individuals to 
obtain average expression level of the samples and the pool was used as calibrator.  
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4.3.2 Real-time PCR 
Real-time PCR was performed in 96-well plates on the LightCycler® 480 instrument. In 
addition to the samples, each PCR run included a calibrator sample (positive control) and at 
least one negative control sample. Sequences of target genes (IL2, IFNG and CSF2) and 
reference genes, 5-aminolevulinate synthase 1 (ALAS1), B2M and ribosomal protein L13A 
(RPL13A) were amplified from the same cDNA pool in separated reactions. Each reaction 
was conducted in triplicate (initial experiments under optimization) or duplicate (MarkIt pilot 
study) to adjust for random variations. The median Cp values based on the two or three 
replicate analyses were used for further calculation of the relative quantification for each gene 
to be evaluated. The reaction mixture consisted of 5 µL cDNA (sample, calibrator or negative 
control), Probes Master 2X conc., gene specific primer pairs (0.5 µM of each for both target 
and reference genes) and hybridization probes (0.15 µM of each for target genes and 0.2 µM 
of each for the reference genes) to a final volume of 20 µL. The cDNA and master mixes of 
reagents were transferred into LightCycler 96-well PCR plates using the MagNA Pure LC 
instrument. After pipetting, the plate was covered with adhesive optical sealing foil, 
centrifuged briefly and then placed into LightCycler® 480 instrument. 
The real-time PCR protocol on the LightCycler® 480 instrument consisted of the following 
programs (Figure 14): 
Program 1: Denaturation  95°C for 10 min 
Program 2: Amplification 95°C for 10 sec, 57°C for 10 sec and 72°C for 10 sec;  
45 cycles 
Program 3: Melt curve analysis 99°C for 5 min, 45°C for 60 sec, gradual increase up to 
70°C  
Program 4: Cooling   40°C for 30 sec 
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Figure 14: Programs on the LightCycler® 480 instrument. 1: denaturation, 2: amplification, 3: melting 
analysis and 4: cooling. The amplification programs consists of steps A – C, repeated for 45 cycles. 
A: denaturation, B: annealing, C: extention/elongation. Fluorescence is measured at the end of each annealing 
step (2B; red box) and continuously during melting in program 3 (green line), providing data for relative 
quantification and melting curve analysis. 
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4.4 qPCR development, optimization and 
validation 
In this project, the qPCR development, optimization and validation focused on the 
amplification and detection of the target genes IL2, IFNG and CSF2. The quantification of the 
reference genes, ALAS1, B2M and RPL13A, has been optimized and validated in previous 
studies [106,107]. 
 
4.4.1 Primer and probes 
The previously established reference gene real-time PCR protocol was utilized further as the 
assay was suitable for amplification of target genes (Section 4.3.2). This implies restrictions 
to the melting temperatures of primers and probes and the length of target gene amplicons. In 
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general, sequence regions with considerable homology with other oligonucleotide sequences 
or known sequence variations was avoided as binding sites for primers and probes. Primers 
and probes were designed using the tools listed in Table 4, as well as manual evaluation of 
sequences.  
 
Table 4: Tools for primer and probe design 
Tool Application 
GenBank 
www.ncbi.nlm.nih.gov/genbank 
 
Target gene transcript sequences were 
retrieved from Genbank, which provides an 
annotated collection of all publicly available 
DNA sequences.   
LightCycler® Probe Design 
Software 2.0 
Suggests potential primer and probe 
sequences and allows analysis of 
oligonucleotide sequences. 
OLIGO Primer Analysis 
Software version 7.22 
Analysis of oligonucleotide sequences. 
Calculations of hybridization temperatures 
and potentially secondary structures 
between or within oligonucleotides 
(provides more detailed information than 
LightCycler® Probe design). 
BLAST (Basic Local Alignment 
Search Tool) 
Analysis of homology between sequences 
(transcript and genomic). 
Alamut, dbSNP and SNPCheck Checks if there are reported sequence 
variants in the binding sites of primers and 
probes. 
 
The selected primer and probe sequences are listed in Table 5. Reference gene sequences are 
listed in Appendix A. The oligonucleotides were synthesized by TIB MOLBIOL. Lyophilized 
primers and probes were dissolved in Tris-EDTA buffer to a concentration of 20 µM and 
6 µM, respectively, and divided into small aliquots to avoid repeated freezing and thawing. 
The primer and probe solutions were stored at −20°C. 
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Table 5: Primer and probe sequences  
Gene Name Sequence  
IL2 IL2_F1 AAACTTTCACTTAAGACCCAG 
  IL2_R1 AGTGTTGAGATGATGCTTTG 
  IL2_FL1 GGGATCTGAAACAACATTCATGTGTG-Fluorescein 
  IL2_LC1 LC Red 640-TATGCTGATGAGACAGCAACCATTGTAGAATTT-Phosphate 
IFNG IFNG_F1 GCAGAGCCAAATTGTCTCCT 
  IFNG_R1 ATGCTCTTCGACCTCGAAAC 
  IFNG_FL1 AACTGTCGCCAGCAGCTA-Fluorescein 
  IFNG_LC1 LC Red 640-ACAGGGAAGCGAAAAAGGAGTCAG-Phosphate 
CSF2 CSF2_F1 TTGAAAGTTTCAAAGAGAACCT 
  CSF2_R1 GATGACCATCCTGAGTTTCTA 
  CSF2_FL1 GACTGCTGGGAGCCAGTC-Fluorescein 
  CSF2_LC1 LC Red 640-GGAGTGAGACCGGCCAGATGAG-Phosphate 
 
Abbreviations: F1; forward primer, R1: reverse primer, FL1; forward probe, LC1; reverse probe 
 
4.4.2 Optimization of primer concentrations 
The primer concentrations were titrated to optimize PCR-efficiency while maintaining 
specificity. For each primer set (forward and reverse primer) of target genes, concentrations of 
0.25 µM, 0.50 µM, 0.75 µM and 1.0 µM were tested in different combinations. The different 
primer concentrations were evaluated based on Cp values and the shape of the amplification 
curves. 
 
 
4.5 Assay validation 
Assay validation focused on the target genes IL2, IFNG and CSF2 as the reference genes have 
been established and validated in previous projects. The selectivity of the primers and probes 
was evaluated by SYBR Green I melting curve analysis, gel electrophoresis and DNA 
sequencing. Standard curves were constructed to determine the PCR-efficiency, dynamic 
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range, sensitivity and limit of quantification of each target gene. The precision of the method 
were evaluated within-runs and between runs.  
 
4.5.1 SYBR Green I melting curve analysis 
Target gene amplicons were studied by SYBR Green I melting curve analysis using the 
LightCycler® 480 SYBR Green I Master kit according to the manufacturer’s instructions. 
Following 45 PCR cycles, the melting program started with a denaturation step at 95°C for 
5 min and reduction to 38°C before a gradual increase from 38 up to 90°C (ramping rate of 
2.2°C/sec) with continuous monitoring of fluorescence (Figure 14 Section 4.3.2). The 
resulting melting curves were evaluated using the Tm Calling Analysis tool of the 
LightCycler® 480 software. The analysis also displays the melting curves as melting peaks by 
plotting the first negative derivative of the fluorescence curves versus temperature. This 
allows easier visualization of the melting temperatures of different samples.  
 
4.5.2 Gel electrophoresis 
For each target gene, 5 µL of PCR product was mixed with 1 µL gel-loading buffer 6X with 
bromophenol blue and loaded into the wells of a 4% NuSieve 3:1 Plus Agarose Reliant® Gel 
with ethidium bromide. Furthermore, a molecular weight marker, no. V (Roche) and a 
negative control were included in parallel. The gel was run in tris-borate-EDTA buffer at 
120 volts for approximately 1 hour. Finally, DNA was visualized in UV-light using the 
Biorad Molecular Imager GelDoc XR. 
 
4.5.3 Sanger sequencing  
The PCR products of the target genes were purified with ExoSAP-IT. Each reaction contained 
1 µL PCR product, 2 µL water and 1.2 µL ExoSAP-IT and the mixture was incubated on a 
block cycler at 37°C for 15 min followed by 15 min at 80°C. The following sequencing 
reaction was performed using the BigDye Terminator v3.1 Cycle Sequencing Kit according to 
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the manufacturer’s instructions. Briefly, 13.8 µL Big Dye Terminator master mix including 
ddNTPs was added to the purified PCR product (4.2 µL) followed by 2 µL of either forward 
or reverse primer. The tubes were sealed with caps and centrifuged briefly and placed back in 
the PCR block cycler. The temperature program of the sequencing reaction is summarized in 
Table 6. 
Following sequencing reaction, the fluorescently labeled DNA fragments were separated by 
capillary electrophoresis on the ABI PRISM® 3100 Genetic Analyzer instrument at the 
Department of Medical Genetics, Oslo University Hospital. The sequencing procedure is 
summarized in Figure 15. 
 
Table 6: Sequencing temperature program  
Step Temperature Comments 
1 1.0 °/sec to 96.0 °C Gradual increase 
2 96.0 °C For 1 min 
3 1.0 °/sec to 96.0 °C  
4 96.0 °C For 10 sec 
5 1.0 °/sec to 50.0 °C Gradual decrease 
6 50.0 °C For 5 sec 
7 1.0 °/sec to 60.0 °C Gradual increase 
8 60.0 °C For 4 min 
9 Step 3 – step 8 Steps 3 to 8 are repeated 24 times 
10 1.0 °/sec to 4.0 °C Gradual decrease 
11 4.0 °C Forever – End 
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Figure 15: Overview of the sequencing workflow.  
ddNTPs; dideoxynucleotides 
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4.5.4 Generation of standard curves 
To generate standard curves, target gene sequences were initially amplified without the 
inclusion of probes, and PCR product concentrations were determined by measuring 
absorbance at 260 nm using the Nanodrop® ND-1000 Spectrophotometer. The IL2, IFNG and 
CSF2 amplicons are 168, 290 and 154 nucleotides long, respectively, and the average 
molecular weight of one nucleotide is 330 g/mol. The numbers of cDNA templates were 
calculated according to the following equation: Number of templates/µL = (measured 
concentration g/µL x 6,022 x 1023 copies/mol) / (amplicon length in nucleotides x 330 g/mol). 
Target gene amplicons were serially diluted with water and MS2 RNA (10 µg/mL) to obtain 
dilution series ranging from 107 to 101 templates per reaction. The dilution series were 
amplified by real-time PCR, including four – six parallel reactions per dilution step and 
standard curves were constructed for each target gene by plotting the logarithm of initial copy 
numbers versus the corresponding Cp values (Figure 16). The average PCR-efficiency values 
were determined by three separate standard curves of each gene and calculated according to 
Equation 2.  
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Figure 16: Construction of standard curve. Serially diluted PCR products from 107 to 101 templates/reaction 
were amplified and standard curves were constructed by plotting the logarithm of initial copy numbers versus the 
corresponding crossing point values. 
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Equation 2: Calculation of PCR-efficiency.  
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4.5.5 Assay precision 
The assay precision was determined by calculating the coefficient of variation (CV) of 
relative concentrations and normalized ratios of gene expression. The within-run precision 
was calculated for the entire dynamic range based on the replicates that generated the standard 
curves. Furthermore, within-run precision was determined based on the replicates of actual 
samples with a range of expression levels. The between-run CV was calculated based on 
analysis of the same calibrator sample on 8 different days. 
PCR-efficiency = 10 -1/slope 
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4.6 Quantification of relative gene expression 
Target nucleic acids can be quantified by PCR by absolute or relative quantification 
strategies. The expression of the IL2, IFNG and CSF2 target genes was determined by relative 
quantification, using reference genes for normalization. Furthermore, the assay included 
calibrator normalization and correction for differences in PCR-efficiency as illustrated in 
Figure 17. 
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Figure 17: Quantification of target nucleic acids using either absolute or relative quantification. The 
relative quantification strategy of this project is highlighted in bold. 
qPCR; quantitative PCR 
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4.6.1 Calculation of relative gene expression 
The relative gene expression was determined using the LightCycler 480 Relative 
Quantification Software Version 1.5. Relative concentrations of each target and reference 
gene were calculated based on Cp values and the gene specific average PCR-efficiency, 
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derived from the three standard curves constructed (Section 4.5.4). The relative 
concentrations of each target gene were then normalized to a geometric mean of the three 
reference genes (reference gene index) as given in Equation 3. Moreover, the target/reference 
ratio of each sample divided by the target/reference of a calibrator sample (Equation 4) 
provides a constant calibration point within and between runs. 
 
Relative expression = [IL2] or [IFNG] or [CSF2] 
([ALAS1] x [B2M] x [RP-L13A])1/3
 
Equation 3: Calculation of relative expression. The expression of each target gene is normalized to the 
geometric mean expression of three reference genes.  
ALAS1; 5-aminolevulinate synthase 1, B2M; Beta-2-microglobulin, CSF2; colony stimulating factor 2 
(granulocyte-macrophage), IFNG; interferon gamma, IL2; interleukin 2, RPL13A; ribosomal protein L13A 
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Calibrator normalized 
relative expression
Relative expression
Relative expression
Sample
Calibrator
=
 
Equation 4: Relative expression with calibrator normalization. The target/reference ratio of each sample was 
divided by the target/reference ratio of the calibrator. 
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4.7 Ex vivo exposure to immunosuppressive 
drugs 
The validated assay, including ex vivo stimulation of whole blood, RT and real-time PCR, 
was used to investigate the potential effect of different immunosuppressive drugs on 
NFAT-regulated gene expression.  
CsA, Tac, mycophenolic acid and prednisolone were dissolved in methanol and added to 
whole blood to achieve a range of pharmacologically relevant blood concentrations. The final 
drug concentrations are given in Table 7.  
Drug free whole blood (150 µL) from healthy volunteers was spiked with 2 µL drug solution. 
Immune activation of the whole blood samples was performed by the addition of 150 µL 
PMA and ionomycin for up to 72 hours at 37°C. Potential effects of CsA and Tac were 
investigated in samples from two different individuals, while mycophenolic acid and 
prednisolone only were added to samples from one individual. All experiments included 
controls without both drug and solvent and controls without drug but with methanol alone. 
Further preparations were carried out in the similar way as with the other blood samples as 
presented in Section 4.1 – 4.3 and Figure 19 in Section 5.1.2. 
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Table 7: Ex vivo drug exposure 
_______________________________________________________________________ 
    Drugs   Final concentration in medium  
CNIs    Tac    0.1 nmol/L 
        0.5 nmol/L 
        1.0 nmol/L 
        10 nmol/L 
        100 nmol/L    
    CsA    10 nmol/L 
        100 nmol/L 
        1 000 nmol/L 
        10 000 nmol/L   
Other drugs   Mycophenolic acid  10 µmol/L 
    Prednisolone   1 000 µmol/L    
Abbreviations: CNIs; calcineurin inhibitors, CsA; cyclosporine A, Tac; tacrolimus 
 
 
4.8 Monitoring of NFAT-regulated gene 
expression in Tac treated renal transplant 
recipients  
Before initiation of the MarkIt pilot study, the applicability of the RT-qPCR assay was tested 
by measuring NFAT-regulated gene expression in pre dose and 1.5 hours post dose samples 
from a single renal transplant patient treated with Tac (the patient received other 
immunosuppressive drugs additionally to Tac). 
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4.8.1 MarkIt pilot study  
Finally, the validated NFAT-regulated gene expression assay was used to investigate the PD 
response of Tac among 5 renal transplant recipients included in the MarkIt pilot study. 
Further details of the study are provided in Section 3.2.  
Blood samples from patients were processed as described in Section 4.1 – 4.3 and the relative 
gene expression was calculated as described in Equations 3 and 4 Section 4.6.1. 
Furthermore, the residual gene expression 1.5 hours after oral administration of Tac was 
calculated by normalizing the expression 1.5 hours post dose (E1.5) to the expression pre dose 
(E0) for each target gene, as presented in Equation 5. Finally, the NFAT-regulated gene 
response was determined based on the geometric mean of IL2, IFNG and CSF2 residual 
expressions.  
 
E1.5
E0
x 100%Residual gene expression =
 
Equation 5: Calculation of residual gene expression. E0 and E1.5 represent the relative expression of target 
genes before and 1.5 hours after Tac dosing, respectively. 
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In addition to the measurements of NFAT-regulated gene expression, other projects of the 
MarkIt study include analyses like genotyping, metabolic activity, IMPDH activity, level of 
purine base and cytokine secretion.  
Tac concentrations were measured in whole blood using chemoluminescent microparticle 
immunoassay (CMIA) on the Architect® platform (Abbott Laboratories, Abbott Park, IL, 
USA). 
CYP3A5-genotyping was performed with DNA extraction from EDTA anti-coagulated whole 
blood using the MagNA Pure LC instrument and MagNA Pure LC DNA Isolation Kit I 
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according to the manufacturer’s instructions. CYP3A5-genotyping (rs776746; 
NG_007938.1:g.12083G>A, A = CYP3A5*1 and G = CYP3A5*3) was performed by PCR 
and melt curve analysis with specific primers and hybridization probes on the 
LightCycler® 480 instrument. Primers were designed using LightCycler Probe Design 
software version 2 and hybridization probe sequences were derived from Cheung et al [108]. 
Demographic and clinical data of the participants in the study were collected and evaluated 
closely during routine examinations. 
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5 Results  
5.1 Assay development and validation 
5.1.1 Lymphocyte activation and sample preparation 
The three different principles for lymphocyte activation (1: PHA, 2: PMA + ionomycin, 
3: PHA + PMA + ionomycin) resulted in considerable increases in expression levels of the 
NFAT-regulated genes IL2, IFNG and CSF2. The highest expression levels were observed 
after 3 hours stimulation with PMA and ionomycin and the combination of PHA, PMA and 
ionomycin (Figure 18). Without immune activation, the expression of IL2, IFNG and CSF2 
was very low (Cp values of target genes > 35 versus reference genes 20 – 29). When whole 
blood was activated with PMA and ionomycin for 3 hours, the expression increased 120 000, 
20 000 and 8 000 fold for IL2, IFNG and CSF2, respectively, compared to unstimulated cells. 
The up-regulation of IL2, IFNG and CSF2 gene expression was less pronounced (100, 300 
and 50 fold, respectively) after activation with PHA (Figure 18). Whole blood incubation in 
48 and 72 hours was associated with pronounced hemolysis, probably caused by RNA 
degradation, and a considerable increase in the Cp values of both target and reference genes 
(median 3 cycles). Based on the results of these initial experiments, incubation of whole blood 
with PMA and ionomycin for 3 hours at 37°C was selected for ex vivo lymphocyte activation 
in the further studies (Figure 19 Section 5.1.2). 
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Figure 18: Gene expression of A: interleukin 2 (IL2), B: interferon gamma (IFNG) and C: colony 
stimulating factor 2 (granulocyte-macrophage) (CSF2). Ex vivo activation of lymphocytes in whole blood by 
0, 3 and 24 hours incubation with phytohemagglutinin (PHA), phorbol 12-myristate 13-acetate (PMA) in 
combination with ionomycin or all three agents together. 
___________________________________________________________________________ 
 
Results 
52 
5.1.2 Cell lysis procedure 
Direct cell lysis by adding LBB to whole blood was easier to perform and less 
time-consuming compared to a two-step procedure starting with lysis and removal of 
erythrocytes before lysis of leukocytes. In addition, the one-step procedure resulted in 
generally lower Cp values (median 5 cycles for target and reference genes), which indicates 
better RNA yields compared to the two-step cell-lysis procedure. Thus, the one-step cell lysis 
procedure was chosen for further analyses (Figure 19).  
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Figure 19: Assay workflow for the quantification of nuclear factor of activated T cells (NFAT)-regulated 
genes in whole blood samples.  
ALAS1; 5-aminolevulinate synthase 1, B2M; beta-2-microglobulin, CSF2; colony stimulating factor 2 
(granulocyte-macrophage), CNI; calcineurin inhibitor, Cp; crossing point, IFNG; interferon gamma, IL2; 
interleukin 2, LBB; Lysis/Binding Buffer, PMA; phorbol 12-myristate 13-acetate, RPL13A; ribosomal protein 
L13A 
___________________________________________________________________________ 
Results 
53 
5.1.3 Primer titration 
Reaction mixture containing 0.5 µM forward and reverse primer and 0.15 µM of each probe 
resulted in efficient amplification of IL2, IFNG and CSF2 templates (PCR-efficiencies 
ranging from 1.95 to 1.97). The PCR-efficiency was further improved by primer titration. 
Forward and reverse primer concentrations of 0.5 µM + 0.75 µM, 0.5 µM + 0.75µM and 
0.75 µM + 0.75 µM for IL2, IFNG and CSF2, respectively, resulted in approximately 
0.3 cycle lower Cp values indicating further improvement in PCR-efficiencies (optimized 
PCR reagent mixtures are presented in Appendix B). Melt curve analysis with SYBR Green I 
confirmed the formation of one specific target gene product with primer concentrations 
ranging 0.5 – 0.75 µM. The final composition of the target gene PCR reagents used in this 
project is summarized in Table 8.  
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Table 8: PCR reagents for the amplification of target genes   
Reagents Volume per 
reaction
Final 
concentration
Water, PCR-quality 3.0 µL
Primer: IL2_F1 (20 uM) 0.5 µL 0.5 µM 
Primer: IL2_R1 (20 uM) 0.5 µL 0.5 µM 
Probe: IL2_FL1 (6 uM) 0.5 µL 0.15 µM 
Probe: IL2_LC1 (6 uM) 0.5 µL 0.15 µM 
LightCycler® 480 Probes 
Master (2X) 10 µL
Master mix total 15 µL
Sample: cDNA 5 µL
Total 20 µL
Master mix IL2
  
Reagents Volume per 
reaction
Final 
concentration
Water, PCR-quality 3.0 µL
Primer: IFNG_F1 (20 uM) 0.5 µL 0.5 µM 
Primer: IFNG_R1 (20 uM) 0.5 µL 0.5 µM 
Probe: IFNG_FL1 (6 uM) 0.5 µL 0.15 µM 
Probe: IFNG_LC1 (6 uM) 0.5 µL 0.15 µM 
LightCycler® 480 Probes 
Master (2X) 10 µL
Master mix total 15 µL
Sample: cDNA 5 µL
Total 20 µL
Master mix IFNG
 
Reagents Volume per 
reaction
Final 
concentration
Water, PCR-quality 3.0 µL
Primer: CSF2_F1 (20 uM) 0.5 µL 0.5 µM 
Primer: CSF2_R1 (20 uM) 0.5 µL 0.5 µM 
Probe: CSF2_FL1 (6 uM) 0.5 µL 0.15 µM 
Probe: CSF2_LC1 (6 uM) 0.5 µL 0.15 µM 
LightCycler® 480 Probes 
Master (2X) 10 µL
Master mix total 15 µL
Sample: cDNA 5 µL
Total 20 µL
Master mix CSF2
 
 
Results 
55 
5.1.4 Primer selectivity  
Melting curve analysis with SYBR Green I demonstrated single, symmetrical peaks at the 
expected melting temperature, approximately 80°C, 87°C and 89°C for IL2, IFNG and CSF2 
amplicons, respectively (Figure 20). The corresponding calculated melting temperature values 
reported by OLIGO were 80 – 84°C, 83 – 87°C and 86 – 90°C for IL2, IFNG and CSF2. Gel 
electrophoresis demonstrated single PCR products for IL2, IFNG and CSF2 at the expected 
sizes of 168, 290 and 154 base pairs (Figure 21). Furthermore, Sanger sequencing confirmed 
amplification of the expected target gene transcript sequences (Figure 22). Altogether, these 
results confirmed the integrity of RNA as well as selective amplification of the expected 
target gene sequences. 
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Figure 20: SYBR Green I melting curve analysis of A: interleukin 2 (IL2), B: interferon gamma (IFNG) 
and C: colony stimulating factor 2 (granulocyte-macrophage) (CSF2) amplicons (blue lines). The red line 
represents the negative control. The negative first derivate of the change in fluorescence plotted as a function of 
temperature.  
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Figure 21: Gel electrophoresis of interleukin 2 (IL2), interferon gamma (IFNG) and colony stimulating 
factor 2 (granulocyte-macrophage) (CSF2) amplicons. The gel includes a molecular weight marker, no. V 
(Roche) and a negative control sample.  
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A: IL2
Reverse primer
 
 
B: IFNG
Reverse primer
 
 
C: CSF2
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Figure 22: Sequencing of A: interleukin 2 (IL2), B: interferon gamma (IFNG) and C: colony stimulating 
factor 2 (granulocyte-macrophage) (CSF2) PCR products (reverse primer). The sequencing results (forward 
and reverse primers) demonstrated amplification of the expected target sequences. Each terminal base is 
represented by a different colour for sequence reconstruction. 
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5.1.5 PCR-efficiency and linear range 
Real-time PCR of IL2, IFNG and CSF2 sequences from serially diluted cDNA template 
generated amplification plots as illustrated in Figure 23. Based on replicates of the standard 
curves, within-run CVs were ≤ 13.6 % for the target gene reactions starting with 107 to 104 
templates per reaction. Furthermore, within-run CVs based on replicates of actual samples 
(Cp values of 31 to 36) were ≤ 13.9%, 19.8% and 16.4% for IL2, IFNG and CSF2 reactions, 
respectively, starting with 107 to 104 templates per reaction. The between-run CV of target 
gene relative expression levels was ≤ 14.8% (Cp values below 33). Starting concentrations of 
10 templates per reaction (5 double stranded molecules) did not consistently result in 
amplification curves, suggesting a lower limit of detection of 102 templates per reaction. 
Based on Equation 2 (Section 4.5.4), mean PCR-efficiencies of IL2, IFNG and CSF2 were 
calculated to 1.96, 1.95 and 1.97, respectively. Furthermore, the standard curves were linear 
over a concentration range from 107 – 102 templates per reaction (Figure 24). The mean 
squared error of the single data points fit to the regression line of the standard curves were 
below 0.02 (an acceptable value should be < 0.2 according to the LightCycler Operator’s 
manual), confirming the precision of the pipetting and real-time PCR. 
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Figure 23: Amplification plots of serially diluted cDNA ranging from 107 – 102 templates/reaction for A: 
interleukin 2 (IL2), B: interferon gamma (IFNG) and C: colony stimulating factor 2 (granulocyte-
macrophage) (CSF2). 
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Figure 24: Example of standard curves generated from the amplification plots of serially diluted (6 fold) 
cDNA for A: interleukin 2 (IL2), B: interferon gamma (IFNG) and C: colony stimulating factor 2 
(granulocyte-macrophage) (CSF2).  Crossing point values were plotted against log cDNA concentrations.  
___________________________________________________________________________ 
Results 
62 
5.2 Effect of immunosuppressive drugs on 
NFAT-regulated gene expression 
Because the investigated drugs were dissolved in methanol, the potential drug effects were 
determined in relation to control samples with methanol only. Following exposure to CsA 
1000 nmol/L (1203 µg/L) for 3 hours, the NFAT-regulated gene expression (combined 
response of IL2, IFNG and CSF2) was reduced by 90% (Figure 25). A similar response was 
observed for Tac, resulting in 80 – 90% and 97% inhibition of expression after exposure to 
Tac 50 nmol/L (41 µg/L) and Tac 100 nmol/L (82 µg/L), respectively (n = 2, Figure 26). 
Lower CNI concentrations (Tac 10 nmol/L and CsA 100 nmol/L) were associated with less 
inhibition (0 – 50%) and higher expression levels, suggesting an inverse relation between 
NFAT-regulated gene expression and CNI concentrations. Prednisolone 1000 nmol/L (360 
mg/L) tended to slightly reduce the IL2, IFNG and CSF2 expression levels, while 
mycophenolic acid 10 µmol/L (3 mg/L) did not have any clear impact on expression of 
NFAT-regulated genes (Figure 25). The responses after drug exposure differed between the 
individual cytokines, and CsA and Tac appeared to have the strongest impact on IL2 and 
CSF2 expression levels (Figure 25 and 27).  
Comparison of expression levels in control samples with and without methanol demonstrated 
that methanol alone (final concentration of 2%, v/w) reduced NFAT-regulated gene 
expression levels by approximately 30% (data not shown). This implies that the results of the 
ex vivo drug exposure experiments are not directly transferable to drug response in vivo. 
Furthermore, the expression observed after 3 hours ex vivo incubation with drugs in a mixture 
of whole blood and activation medium may not necessarily reflects the response in vivo 
(e.g. differences in drug binding and exposure). Because of this, the following experiments 
involved samples from patients with in vivo exposure to CNIs. 
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Figure 25: Relative expression nuclear factor of activated T cells (NFAT)-regulated genes. Ex vivo 
activation in 3 hours with addition of phorbol 12-myristate 13-acetate and ionomycin. Effects of mycophenolic 
acid (MPA) 10 µmol/L, cyclosporine (CsA) 1000 nmol/L and prednisolone (Pred) 1000 µmol/L. The results 
were normalized to control samples where the CNI/methanol solution was replaced by methanol only.  
CSF2; colony stimulating factor 2 (granulocyte-macrophage), IFNG; interferon gamma, IL2; interleukin 2 
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Figure 26: Relative expression nuclear factor of activated T cells (NFAT)-regulated genes. Quantitative 
analysis of the total NFAT-regulated gene expression after ex vivo exposure to different concentrations of 
tacrolimus (Tac) and cyclosporine (CsA). The results were normalized to control samples were the 
CNI/methanol solution was replaced by methanol only.  
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5.3 Expression of NFAT-regulated genes in Tac 
treated renal transplant recipients  
Before starting the enrollment of patients in the pilot study, the utility of the assay was 
confirmed by measurement of NFAT-regulated gene expression in blood samples from a 
single renal transplant recipient treated with Tac. In this patient the residual expression of the 
combined NFAT-regulated genes (expression 1.5 hours post dose versus pre dose) was 14% 
as shown in Figure 27. The pre dose and 1.5 hours post dose concentrations of Tac were 
5.1 µg/L and 15.9 µg/L, respectively. 
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Figure 27: Residual expression of nuclear factor of activated T cells (NFAT)-regulated genes. The 
expression measured in a transplant patient before and 1.5 hours after administration of tacrolimus. See 
Section 4.6.1 for calculation.  
CSF2; colony stimulating factor 2 (granulocyte-macrophage), IFNG; interferon gamma, IL2; interleukin 2 
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5.3.1 MarkIt pilot study 
During the time of the present master project, five participants receiving their first graft were 
included in the pilot study. Demographic and clinical data are summarized in Table 9. The 
limited number of patients included in the study so far did not permit statically testing and the 
results are presented as individual data or median and range of values.  
There was a large variability (approximately 5 fold) in NFAT-regulated gene expression 
before Tx between the five participants of the pilot study. Approximately one week post Tx, 
the gene expression (pre dose) was considerably reduced among three patients and relatively 
stable among the other two patients, compared to pre Tx levels (Figure 28).  
Following Tac (Prograf) dosing, the expression of the NFAT-regulated genes was rapidly 
down-regulated and the response differed between patients. Four patients demonstrated 
residual gene expression levels below 13%, while one patient presented a residual expression 
of 27% at 1.5 hours after Tac dosing (Figure 29).  
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Figure 28: Relative expression of nuclear factor of activated T cells (NFAT)-regulated genes. The 
expression measured in 0 – 4 days pre transplantation (Tx) and pre dose at approximately one week post Tx 
following the initiation of standard tacrolimus therapy.  
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Figure 29: Residual expression of nuclear factor of activated T cells (NFAT)-regulated genes 1.5 hours 
after tacrolimus dosing. Five renal transplant recipients approximately one week after transplantation.  
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Tac treatment was initiated on the day of Tx, starting with fixed doses of approximately 
0.04 mg/kg twice a day, followed by dose adjustments to obtain pre dose concentrations 
within the therapeutic range (< 6 months post Tx: 3 – 7 µg/L and 3 – 5 µg/L after 6 months) 
according to the Tx protocol at the time of the study [24]. The pre dose and 1.5 hours post 
dose Tac concentrations of the patients approximately one week post Tx are listed in 
Table 10. 
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Table 9: Demographic characteristics and clinical data in the MarkIt pilot study 
901 902 903 904 905
Sex (M/F) M M F M F
Age (year) 57 37 67 20 54
Bodyweight (kg) 97 96.5 74 76 58.9
Dialysis pre transplant (yes/no) no no no yes yes
CYP3A5 *3/*3 *3/*3 *1/*3 *3/*3 *3/*3
HLA - mismatch (DR) 4 - 2 3 - 1 1 - 1 1 - 1 0 - 0
Donor specific antibody – – –
Anti-DQ7 
Crossmatch 
negative
–
Immunosuppression post 
transplant Standard regimen  Standard regimen Standard regimen DSA protocol A HLA protocol B
Complications first weeks post 
transplant
–
4 days: Increase of 
creatinine C and 
rejection D
72 days: 
Polyomavirus (BK) 
positive
–
3 days:             
Ureteral leak 
Reoperation
Patient (n = 5)
 
 
– Standard regimen: Mycophenolat mofetil (MMF), Tacrolimus (Tac: Prograf, Advagraf), Prednisolon (Pred)  
   and Basiliximab 
A: DSA protocol: Standard regimen + Rituximab 375 mg 2 – 4 weeks pre Tx + MabThera (one dose) and Kiovig   
    for 5 subsequent days post Tx 
B: HLA Protocol: Standard regimen without MMF  
C: Increase of serum creatinine from 189 – 250 µmol/L within one day.  
D: Biopsy-proven acute rejection: both cellular and humoral. Reversed following Solu-Medrol (500 mg daily) for       
    4 subsequent days post Tx. 
Abbreviations: F; female, HLA; human leukocyte antigen, M; male 
___________________________________________________________________________ 
 
 
Table 10: Pre and 1.5 hours post dose concentrations and doses of Tac approximately one 
week after Tx 
Tac C0 (µg/L) Tac C1.5 (µg/L) Dose (mg/kg)
Patient 1 6.4 15.0 0.03
Patient 2 5.3 22.9 0.05
Patient 3 5.2 16.4 0.05
Patient 4 10.6 >30.0 0.08
Patient 5 4.6 6.3 0.04
 
Abbreviation: Tac; tacrolimus 
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6 Discussion 
The introduction of CNIs has contributed to reduce the incidence of acute rejection episodes 
to as low as 10% the first year after Tx and CNIs are now included in most 
immunosuppressive regimens after organ Tx. However, despite the efficacy of CNIs, their use 
is restricted by severe side effects such as nephrotoxicity, neurotoxicity, hypertension, 
diabetes and gastrointestinal disorders [109,110]. The long-term outcomes after Tx have not 
improved in parallel with short-term outcomes [79], and this may, at least partially, be 
explained by the negative impact of CNI toxicity on long-term outcomes.  
The risks and benefits of low-dose CNI or elimination of CNI after Tx have been examined in 
several studies. More et al. showed that the use of mycophenolate mofetil (prodrug of 
mycophenolic acid) in CNI sparing regimens was associated with improved short-term renal 
function and possibly improved graft survival on long-term outcomes [111].  In the BENEFIT 
(Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression 
Trial) study, 686 patients were randomized to receive a more intensive regimen of belatacept 
(Nulojix), a less intensive regimen of belatacept or CsA. Patients receiving either a more or 
less intense regimen of belatacept experienced better renal function and overall patient/graft 
survival but had higher incidence and grade of acute rejection compared to CsA treated 
patients [112].  
Both CsA and Tac have a narrow therapeutic window and a close monitoring of these drugs is 
required to avoid the risk of over- or underimmunosuppression in the individual patient. 
Adequate immunosuppression is especially important during the first days post Tx. The 
results of monitoring based on C0 are suboptimal and full AUC0-12h and abbreviated AUCs 
(0 – 6 hours or 0 – 4 hours) have been reported to better correlate with clinical outcomes. 
However, AUC
 
monitoring in each patient is not feasible in clinical routine practice. Several 
studies have proposed that Cmax levels of CsA and Tac, measured 2 and 1.5 hours post dose, 
respectively, better predict the clinical response of the drugs as compared to C0 levels 
[29,74,113]. However, a systematic review showed that the benefit of C2 with respect to C0 
levels could not be demonstrated and monitoring of C0 levels is still regarded the standard of 
care in many Tx centers [114]. Recently, Zahn et al. confirmed that the maximum inhibition 
of PMA and ionomycin-induced expression of NFAT-regulated genes was obtained 1.5 hours 
after oral administration of Tac [77]. 
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Measurement of whole blood concentrations of CNIs does not necessarily reflect the 
biological response in immune cells, and measurement of PD response biomarkers may better 
predict the clinical response of the drugs. Although differing in chemical structure (Figure 3), 
both CNIs prevent activation of the transcription factor NFAT and thereby the transcription of 
several cytokines essential for lymphocyte activation and proliferation.  
The majority of studies have investigated NFAT-regulated gene expression responses during 
CsA therapy in stable renal Tx patients. Compared to CsA, Tac has been associated with a 
lower risk of acute rejection in the early phase after Tx [29-36]. Currently, the use of Tac is 
increasing although only few data exist addressing the outcome in Tac treated patients in early 
phase post transplant. Tac has replaced CsA in many immunosuppressive protocols, including 
the standard immunosuppressive protocol for renal Tx at Oslo University Hospital. In parallel 
to CsA, NFAT-regulated gene expression has been suggested as a promising tool for PD 
monitoring of Tac therapy in different transplant patient populations [30,76,77,80,92,105]. 
The patients included are both de novo pediatric, adult and senior transplant patients (e.g. 
renal, heart, liver or lung) and stable transplant patients [56,90-92]. The variability in gene 
expression responses between patients suggests individual differences in immunosuppressive 
responsiveness to CNI. However the gene expression response appears to differ between CsA 
and Tac [30], and further studies are needed to characterize potential associations between 
NFAT-regulated gene expression and clinical outcomes in Tac treated patients. The initial 
part of the present project focused on the development of a useful assay for determination of 
NFAT-regulated gene expression in whole blood. Subsequently, the assay was used to 
investigate the NFAT-regulated gene expression as potential PD biomarkers among Tac 
treated patients in the early phase after renal Tx. 
 
6.1 Assay for determination of NFAT-regulated 
gene expression in whole blood  
Traditionally, gene expression measurements involved Northern blotting techniques or 
semi-quantitative RT-PCR. The more recently introduced RT-qPCR provides rapid and 
reproducible quantification of mRNA over a wide range of concentrations. The purpose of 
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this project was to develop and validate a real-time PCR based assay for the quantification of 
IL2, IFNG and CSF2 gene expression to monitor Tac response in renal transplant patients.  
 
6.1.1 Sample preparations 
In the initial studies, peripheral blood mononuclear cells were isolated before ex vivo 
activation [105]. The isolation procedure may affect cellular responses and eliminate plasma 
components and thereby influence the measured NFAT-regulated gene expression. Compared 
to activation of isolated cells, activation of lymphocytes in whole blood minimizes sample-
handling steps, is less time-consuming and may better reflect the in vivo physiological 
environment since all cellular blood components, including drugs and the metabolites are 
present [115,116]. CNIs are extensively bound to erythrocytes and since approximately 90% 
of the drugs are bound in the cellular component in blood it was decided to activate the 
lymphocytes and thereby measure the CNI concentration in whole blood [117,118].  
Cytokines play a crucial role in the immune response towards a transplanted allograft. Their 
expression levels affect many signal cascades, including the differentiation of naive T cells 
into effector T cells. Exposure to clinically relevant concentrations of CsA and Tac has been 
reported to down-regulate the expression of IL2, TNF-α, INFG and CSF2 [92]. The 
expression of the individual cytokines may be influenced by different factors, and 
measurement of a combined response of multiple cytokines probably provides more robust 
assessment of the CNI response compared with measurement of single cytokines [119]. 
Because the expression of TNF-α in whole blood is low and variable, NFAT-regulated gene 
expression responses were calculated based on IL2, INFG and CSF2 gene expression levels 
only [92]. Giese et al. confirmed that the measurement of these three cytokines in whole 
blood is reproducible and that these biomarkers can be effectively used in gene 
expression [105].  
In the previously published gene expression assays, lymphocytes were activated ex vivo with 
PMA and ionomycin [30,76,77,80,92,105,120]. The present project is part of a bigger study 
involving measurement of several potential biomarkers. Different principles of lymphocyte 
activation were tested to identify a common activation strategy suitable for the different 
assays. Corresponding to previous findings, the highest expression levels of NFAT-regulated 
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genes were obtained after 3 hours incubation with PMA and ionomycin. Incubation for 48 and 
72 hours was associated with pronounced hemolysis and degradation of RNA. The relatively 
short incubation period of 3 hours is favorable considering potential use of the assay in 
clinical routine. PMA and ionomycin was also a suitable lymphocyte activation principle for 
the assessment of other potential PD biomarkers in parallel studies. Using the same 
lymphocyte activation principle in studies of different biomarker responses, allows more 
direct comparison of the results.  
Compared to the previously published assays, the present method involves a simplified 
one-step lysis procedure. This provides a simpler, faster and more robust sample preparation 
procedure, as well as increased yields of mRNA. The time to RNA stabilization is reduced 
and potential regulation of gene expression during the red blood cell lysis procedure is 
avoided. Altogether, the sample preparation steps were easy to perform and could be carried 
out within one day with high intra-and interassay reproducibility. 
 
6.1.2 Gene expression assay 
The MagNA Pure LC instrument allowed automated RNA isolation from up to 32 different 
samples in one batch. Furthermore, the pipetting function of the instrument was utilized to 
transfer cDNA and PCR reagents into LightCycler 96-well plates. The use of a closed and 
automated system for the RNA isolation and PCR preparation steps minimizes manual 
pipetting errors, reduces the risk of contamination, reduces hands-on time and improves the 
assay precision.  
The two-step RT-PCR procedure allowed individual optimization of the RT and PCR 
reactions. This provides greater flexibility in the selection of polymerases and priming 
strategies and allows multiple PCR reactions to be performed from a single cDNA sample. 
In preliminary NFAT gene expression assays, RT was performed by avian myeloblastosis 
virus reverse transcriptase and oligo(dT) primers [77,105]. The present assay utilized the 
Transcriptor First Strand cDNA Synthesis Kit to ensure efficient RT of both target and 
reference genes. The thermostability of the Transcriptor enzyme allowed RT reactions to be 
performed at temperatures up to 65°C, reducing potential RNA secondary structures. 
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Furthermore, in contrast to the avian myeloblastosis virus enzyme, the RNase H positive 
Transcriptor enzyme degrades RNA in RNA-DNA hybrids, preserving the quantity of the 
original material. A combination of random hexamer and anchored-oligo(dT)18 primers 
generally improved RT efficiency, demonstrated by lower Cp values, compared to using a 
single priming strategy. Oligo(dT)18 primers initiate cDNA synthesis at the poly(A) tail of 
mRNA, generating full-length cDNAs. However, the efficacy of oligo(dT)18 priming may 
vary depending on the distance from the poly(A) tail. Random hexamer primers bind to many 
sites throughout the length of RNA. The present assay involves analysis of several sequences 
with different locations in relation to poly(A) tails. Thus, combining random hexamer and 
anchored-oligo(dT)18 primers are thought to provide a more uniform representation of the 
RNA sequences of interest. 
Our previously established reference gene assays are based on product detection using 
hybridization probes. The same format was also selected for the detection of target gene 
amplicons, facilitating the use of a single PCR program and automated data analysis. 
Hybridization probes offer an additional level of selectivity as the FRET process and signal 
emission only occurs if both probes are bound to their complementary sequences 
simultaneously. However, compared to the SYBR Green I format used in the reported 
assays [30,77,92,105,120], hybridization probes are more expensive.  
Following identification of suitable primers and probes, the assay design and optimization 
procedure included titration of the primer concentrations. Too high primer concentrations may 
result in the formation of primer dimers and non-specific products, while too low 
concentrations may reduce the PCR-efficiency. The optimal primer concentrations were 
selected based on SYBR Green I analysis and Cp values of amplification plots, indicating 
primer selectivity and PCR-efficiency, respectively. 
Normalization of the expression of target genes to reference genes corrects for non-biological 
variation due to e.g. differences in template input quality or quantity and the yields of RNA 
isolation and RT. An optimal reference gene should be stably expressed under all 
experimental conditions and the expression levels should be in the same range as the 
expression of the target gene of interest. However, as there is no single reference gene with 
constant expression under all conditions, use of a combination of at least three different 
validated reference genes has been recommended [101,121]. The selection of stable reference 
genes is critical for a reliable and robust normalization of the target gene expression. In the 
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preliminary published NFAT-regulated gene expression assays, target gene expression was 
normalized to the mean expression of beta-actin and cyclophilin B [76,77,105]. Several 
studies have shown that the expression of reference genes like beta-actin is altered under 
different experimental conditions [100,122,123]. To minimize the impact of potential gene 
regulation and strengthen the accuracy of the present assay, gene expression was normalized 
to the geometric mean expression of three different reference genes. The reference genes 
ALAS1, B2M and RPL13A have been reported to be constitutively expressed in most cell 
types [99] and belong to different functional classes, thereby minimizing the risk of 
coregulation. Moreover, the expression of the selected reference genes in blood cells has been 
validated in previous experiments in our laboratory [106,107]. See Section 1.6.4.1 for more 
details.  
To further minimize potential non-biological variability, the target/reference ratio of the 
sample was normalized to the target/reference ratio of the calibrator sample included in each 
run. This corrects for differences in detection sensitivity between target and reference genes 
caused by differences in probe annealing, FRET efficiency, or dye extension coefficients. 
Additionally, such normalization provides a constant calibration point between runs and 
makes the processing assay relatively robust. Because of the instability of RNA, a cDNA 
calibrator was used for normalization in the present assay.  
The calculation of relative gene expression levels is based on Cp values and PCR efficiencies 
of target and reference genes. Generally, most amplification reactions do not reach 100% 
efficiency. The PCR efficiency may vary due to the presence of PCR inhibitors or 
inappropriate primer and/or probe design, e.g. targeting GC-rich sequences or resulting in 
coamplification of nonspecific PCR products. Compounds known to inhibit PCR include 
SYBR Green I, heparin, hemoglobin, lipids, polysaccharides and various sample preparation 
reagents (phenol, ethanol, proteinase K and paramagnetic silica beads) as mentioned in 
Section 1.6.4. The estimated PCR efficiencies were above 97.5% for all target and reference 
gene reactions, and this is well within the acceptable range of 90 to 110% efficiency 
according to the Roche manual. To correct for differences in PCR efficiency, the actual gene 
specific efficiencies were determined by dilution series experiments and included in the 
relative gene expression calculations (Equation 3 and 4 Section 4.6.1).  
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6.2 Assay validation  
The quality of every PCR assay depends on the use of selective primers. Although the 
selectivity of primers and probes was evaluated in silico by different software tools, selective 
amplification and detection of products should also be confirmed experimentally. The 
selectivity of the primers and probes of the present assay was confirmed by three different 
techniques, SYBR Green I analysis, gel electrophoresis and direct sequencing, providing 
complementary information of the present amplicons. Furthermore, the suitability of the 
primer design was confirmed by the efficient amplification of target and reference gene 
sequences (discussed in Section 6.1.2). 
Transplanted patients demonstrated a wide range in their leukocyte counts. Furthermore, the 
relative expression levels of IL2, IFNG and CSF2 may vary considerable due to the 
immunosuppressive therapy and immunological conditions. This requires reliable 
quantification of gene expression over a wide range of mRNA concentrations. Analysis of 
repeated generation of standard curves demonstrated linearity over a range of 107 – 102 
templates per reaction, indicating constant amplification efficiencies over the concentration 
range studied. Single-template detection is theoretically possible with real-time PCR. 
However, the distribution statistics at low template concentrations influence the actual lower 
limit of detection. The accuracy and the precision levels have been calculated on the basis of 
Cp values. The log–linear inverse relationship between concentrations and Cp values 
indicates that CVs based on relative concentrations will be nominally higher than CVs based 
on Cp values. The CVs of the present assay were calculated in terms of relative 
concentrations. These CVs are directly applicable and relevant for the interpretation of results 
presented in terms of relative concentrations. The within and between assay CVs were below 
19.8% (107 – 104 templates per reaction) and 14.8%, respectively, which is regarded highly 
acceptable for this type of assay. Analysis of cytokine expression in patient samples resulted 
in Cp values < 35 (corresponding to 104 templates per reaction). This confirms precise 
quantification in the range of clinically relevant template concentrations.  
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6.3 Effect of ex vivo exposure to 
immunosuppressive drugs 
NFAT-regulated gene expression was quantified in blood samples after incubation with 
different immunosuppressive drugs and concentrations ex vivo. A previous report by Giese et 
al. showed a CNIs exposure-dependent regulation of NFAT-regulated genes [92]. A similar 
concentration dependent NFAT-regulated gene expression response was demonstrated, 
whereas up to 100% inhibition was observed at the highest concentration of each CNI 
(Figure 26). As previously reported, IL2 and CSF2 gene expression appears to demonstrate a 
higher sensitivity to CNIs compared to IFNG expression [91]. Only smaller alterations of 
NFAT-regulated genes were observed after incubation with Pred, while the gene expression 
was relatively stable following exposure to mycophenolic acid (Figure 25). NFAT-regulated 
genes appear to be most strongly expressed to the effects of CNI in vivo compared to 
prednisolone and mycophenolic acid. This is in agreement with previous studies [87,124]. 
The observed effect of methanol alone on the NFAT-regulated gene expression represents a 
major limitation of the ex vivo drug exposure experiments. Although the gene expression 
response after ex vivo drug exposure was related to the control sample with methanol, the 
observed responses to different immunosuppressive drugs and concentrations may not reflect 
the actual immune response in vivo. Furthermore, the intracellular concentration of CNIs 
within lymphocytes is likely to differ after ex vivo versus in vivo drug exposure due to 
differences in matrix effects and drug distribution.  
 
 
6.4 NFAT-regulated gene expression in renal 
transplant recipients treated with Tac 
To further confirm the utility of the assay, the NFAT-regulated gene expression was 
determined in samples from a renal transplant recipient receiving Tac therapy. Several studies 
have reported an association between residual gene expression, calculated by normalizing the 
expression at maximum CNI exposure to pre dose expression, and clinical outcomes post 
Tx [30,76,77,80,92,105]. The expected time to reach the Cmax after Tac dosing is about 
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1.5 hours. Samples for NFAT-regulated gene expression analysis were therefore drawn before 
and 1.5 hours after the administration of Tac. The patient demonstrated residual gene 
expression of 14% 1.5 hours after Tac dosing. The Tac concentration was 15.9 µg/L 1.5 hours 
post dose (C1.5) and 5.1 µg/L pre dose (C0). The C0 level was well within the target range of 
Tac C0 between 3 to 7 µg/L. The NFAT gene expression response during in vivo Tac therapy 
was further investigated in the MarkIt pilot study. 
 
6.4.1 MarkIt pilot study 
Despite comparable Tac blood concentrations, the clinical response varies considerably 
among patients. The level of residual NFAT-regulated gene expression has been associated 
with clinical events. Previous studies have proposed that an optimal range of residual 
NFAT-regulated gene expression during CsA therapy should be in the range of 20 – 30% 
[27,77,80]. Stronger inhibition has been associated with an increased risk of infection and 
malignancies, while residual gene expression above 30% may increase the risk of rejection 
episodes. However, the optimal range is primarily based on studies of CsA treated long-term 
stable renal transplant patients and may not directly be relevant for the response in Tac treated 
patients in the early phase after Tx. Mortensen et al. compared the inhibition of calcineurin 
activity in Tac treated patients early after Tx and 5 years later. Exposure to therapeutic Tac 
concentrations resulted in stronger inhibition of calcineurin activity in the early phase post 
transplant compared to 5 years after Tx [125].  
Several studies have demonstrated that the residual gene expression levels are better 
correlated to clinical events compared to CNI blood concentrations [30,76,77,80,92,105]. A 
recent study by Sommerer et al., investigating Tac treated stable renal allograft recipients, 
demonstrated residual NFAT-regulated gene expression levels below 20% to be associated 
with an increased risk of infections (e.g. CMV), while residual expression above 20% was 
associated with an increased risk of acute rejection [126]. However, another study reported 
patients with residual expression above 80% and still not experiencing rejection [30]. A PD 
monitoring study by Billing et al. demonstrated a higher inhibition of NFAT-regulated genes 
in pediatric renal transplant recipients compared to the inhibition in adults. The authors 
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emphasize the need to define the specific target ranges of residual NFAT-regulated gene 
expression in different patient populations [91].  
All five renal transplant recipients included in the MarkIt pilot study demonstrated more than 
70% inhibition of NFAT-regulated gene expression around one week post Tx. Previous 
studies have demonstrated an inverse correlation between the residual NFAT-regulated gene 
expression and serum creatinine levels [127]. One of the participants experienced an acute 
rejection episode four days after Tx. One week post Tx, the residual gene expression level in 
this patient was 1.5%. The almost complete inhibition of NFAT-regulated gene expression 
may be related to the rejection treatment, including four days of high dose i.v. glucocorticoid 
therapy and an increase of Tac doses. 
Sommerer et al. demonstrated a correlation between a high degree of NFAT-regulated genes 
inhibition and an increased risk of adverse effects such as infections and malignancies [127]. 
Among the patients in the MarkIt pilot, four patients had residual NFAT-regulated gene 
expressions of 13% or less, suggesting a high degree of gene expression inhibition in the early 
period after Tx. Three of the patients demonstrated Tac pre dose concentrations within the 
therapeutic range, while one patient presented Tac C0 above target. According to Sommerer 
and colleagues, these patients might benefit from Tac dose reductions [126]. One of the 
patients in the present study demonstrated residual expression of 2.5% and developed 
polyomavirus (BK) infection approximately 2 months post Tx. However, further data are 
needed to characterize potential associations between residual gene expression levels and the 
risk of infections. 
There was a large interindividual variability in the relative gene expression levels (without 
normalization to pre dose values). Before Tx, up to 5 fold differences in NFAT-regulated 
gene expression was observed between individuals (Figure 28). This may be related to 
individual differences in immune status, which in turn may be influenced by previous 
dialysis, uremia, infections, previous blood transfusion, comedication or genetics. Comparing 
the relative gene expression before Tx versus pre dose after Tx, three patients demonstrated a 
reduction in expression levels. This may be explained by the presence of Tac in the pre dose 
samples after Tx. Among the two patients with the lowest pre Tx expression levels, Tx and 
initiation of immunosuppression did not appear to have any profound effect on the relative 
gene expression pre dose (Figure 28). One of these patients had donor specific antibodies 
(DSA) and received immunosuppressive therapy before Tx (Table 9). The considerable 
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variability in NFAT-regulated gene expression levels between patients may indicate different 
immune activation potentials and thereby different requirements for immunosuppression. 
Finally, there has been extensive evidence that CNI PKs may be influenced by 
pharmacogenetic factors within the CYP system. The effects of CYP3A5-genotype on CNI 
PKs have been reviewed in detail by Staatz et al. and more recently by Picard et al. [128,129]. 
A recent study demonstrate that recipients with CYP3A5*1 (CYP3A5 expressers) required a 
higher dose of Tac than CYP3A5*3 homozygote (CYP3A5 nonexpressers) to reach C0 
concentrations [130]. Genotype was determined once for each participant and a genetic 
polymorphism in CYP3A5 was observed, which contributes to variation in distribution of 
Tac. Genotyping in the MarkIt pilot revealed the CYP3A5*3/*3 genotype in four patients, 
while one patient was found to be heterozygous CYP3A5*1/*3. Pharmacogenetic information 
should be taken into consideration as genotyping may identify which patients may need 
higher initial doses for effective immunosuppression during the critical first days after Tx. 
 
 
6.5 Future perspectives 
Despite the many PD monitoring proposals to individualize Tac therapy none of these has 
been implemented in routine clinical practice, an optimal approach still needs to be 
established. Monitoring of NFAT-regulated gene expression has been suggested as a 
promising tool to optimize CNI therapy [29]. However, so far, there are only a few data on de 
novo renal Tx recipients and on patients receiving Tac.  
The optimal range of NFAT-regulated gene expression needs to be established in different 
patient populations and in different phases after Tx. To better characterize the 
NFAT-regulated gene expression in Tac treated patients early after Tx, the next step will be to 
perform the planned enrollment of 30 participants. The relative gene expression and the 
residual gene expression 1.5 hours post Tac dose will be investigated in relation to clinical 
parameters like infections, malignancies, rejection episodes. Furthermore, the gene expression 
response in the early phase (first 8 weeks) will be compared to the response at approximately 
1 year post Tx.  
Discussion 
79 
Although NFAT-regulated gene expression is reported to be relatively CNI specific, 
knowledge of potential factors interacting with the gene expression response is still limited. 
Further studies are needed to study the potential impact of immunosuppressive co-medication, 
infections, the general immune status and genetic factors.    
Several studies suggest measurement of NFAT-regulated gene expression to be a relevant tool 
for preventing over-immunosuppression and CNI induced adverse events 
[30,76,77,80,92,105,120,126,131]. However, data on the relation between residual 
NFAT-regulated gene expression and acute rejection episodes are less consistent. With the 
present immunosuppressive regimens, the number of acute rejection episodes is limited. This 
implies that relatively large studies are required to characterize the relation between 
NFAT-regulated gene expression and acute rejection episodes.  
Before implementation in clinical practice, the value of monitoring NFAT-regulated gene 
expression needs to be confirmed in prospective studies. Monitoring of NFAT-regulated gene 
expression has been suggested as a complementary tool to PK monitoring.  
CYP3A5 play an important role in metabolizing and distribution of Tac and is more recently 
suggested as useful marker to characterize Tac therapy. The correlation between Tac blood 
concentration and the presence of CYP3A5 should be further clarified. 
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7 Conclusion  
To further improve long-term outcomes after solid organ Tx, there is a need for optimization 
of the immunosuppressive therapy. Currently, CNIs are included in most immunosuppressive 
regimens. Monitoring NFAT-regulated gene expression has been suggested as a promising 
approach for individualizing CNI therapy.  
We have established and validated an assay for quantification of IL2, IFNG and CSF2 gene 
expression after ex vivo immune activation. The assay was based on a previously reported 
procedure [30,76,77,80,92,105,120]. The simplified sample preparation involved 3 hours 
incubation of whole blood with PMA and ionomycin, followed by direct lysis of blood cells 
and extraction of total RNA. After RT and real-time PCR, the expression of the target genes 
was normalized to the expression of the reference genes ALAS1, B2M and RPL13A. 
Validation of the RT-qPCR assay confirmed specific and reproducible quantification of the 
target genes.  
The present sample presentation steps improved workflow efficiency compared with 
previously published assay. Additionally, the experimental results could be obtained within 
one day with high intra-and interassay reproducibility.  
Ex vivo exposure of whole blood samples from healthy individuals to clinically relevant CNIs 
concentrations demonstrated an inverse correlation between CNI exposure and 
NFAT-regulated gene expression. In contrast, prednisolone and mycophenolic acid did not 
appear to have any pronounced effect on the NFAT-regulated cytokines. Furthermore, the 
utility of the assay was confirmed by analyzing samples from renal transplant patients 
receiving Tac therapy. The large variability in NFAT-regulated gene expression before Tx 
may suggest interindividual differences in immune status and potentially different 
requirements for immunosuppression. Residual gene expression at 1.5 hours post dose, 
normalized to pre dose levels, has been reported to be associated with clinical outcomes like 
rejection episodes, infections and malignancies [30,77]. About one week post Tx, 4 of 5 
patients demonstrated residual gene expression below the suggested optimal range. However, 
only one of these patients presented Tac C0 levels above the therapeutic target range.  
The preliminary findings support the use of NFAT-regulated gene expression as PD 
biomarker of Tac response. Combined PD and PK monitoring may allow better prediction of 
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the clinical response during Tac therapy. However, further studies are needed to determine the 
optimal PD monitoring strategy in different patient populations. Finally, the benefit of PD 
monitoring needs to be confirmed in larger prospective intervention trials. 
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Appendix A: Reference gene sequences 
Gene Name Sequence  
ALAS1 ALAS1_F1 AATGAGTCGCCACCCACG 
  ALAS1_R1 CAGCTCCCGCTCTAAGTCCA 
  ALAS1_FL1 CCTGCCCCAGCACCATGTTGTTTC-Fluorescein 
  ALAS1_LC1 LC Red640-GTGTCCATAACTGCCCCACACACC- Phosphate 
B2M B2M_F1 GTCTTTCTATCTCTTGTACTAC 
  B2M_R1 GCATCTTCAAACCTCCATGA 
  B2M_FL1 TGACTTTGTCACAGCCCAAGATAGT-Fluorescein 
  B2M_LC1 LC Red640-AAGTGGGATCGAGACATGTAAGCA-Phosphate 
RPL13A RPL13A_F1 CGTGCGTCTGAAGCCTACA 
  RPL13A_R1 GGAGTCCGTGGGTCTTGAG 
  RPL13A_ FL1 CGGTAGTGGATCTTGGCTTTCTCTTTCC-Fluorescein 
  RPL13A_ LC1 LC Red640-CTTCTCCTCCAGGGTGGCTGTCAC-Phosphate 
 
Abbreviations: F1; forward primer, R1: reverse primer, FL1; forward probe, LC1; reverse probe 
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Appendix B: Optimized PCR reaction mixture for target genes 
 
Reagents Volume per 
reaction
Final 
concentration
Water, PCR-quality 2.75 µL
Primer: IL2_F1 (20 uM) 0.5 µL 0.5 µM 
Primer: IL2_R1 (20 uM) 0.75 µL 0.75 µM 
Probe: IL2_FL1 (6 uM) 0.5 µL 0.15 µM 
Probe: IL2_LC1 (6 uM) 0.5 µL 0.15 µM 
LightCycler® 480 Probes 
Master (2X) 10 µL
Master mix total 15 µL
Sample: cDNA 5 µL
Total 20 µL
Master mix IL2
 
 
Reagents Volume per 
reaction
Final 
concentration
Water, PCR-quality 2.75 µL
Primer: IFNG_F1 (20 uM) 0.5 µL 0.5 µM 
Primer: IFNG_R1 (20 uM) 0.75 µL 0.75 µM 
Probe: IFNG_FL1 (6 uM) 0.5 µL 0.15 µM 
Probe: IFNG_LC1 (6 uM) 0.5 µL 0.15 µM 
LightCycler® 480 Probes 
Master (2X) 10 µL
Master mix total 15 µL
Sample: cDNA 5 µL
Total 20 µL
Master mix IFNG
 
 
Reagents Volume per 
reaction
Final 
concentration
Water, PCR-quality 2.5 µL
Primer: CSF2_F1 (20 uM) 0.75 µL 0.75 µM 
Primer: CSF2_R1 (20 uM) 0.75 µL 0.75 µM 
Probe: CSF2_FL1 (6 uM) 0.5 µL 0.15 µM 
Probe: CSF2_LC1 (6 uM) 0.5 µL 0.15 µM 
LightCycler® 480 Probes 
Master (2X) 10 µL
Master mix total 15 µL
Sample: cDNA 5 µL
Total 20 µL
Master mix CSF2
 
